Mechanisms of Immunodeficiency Due To NFkappaB Signaling Defects by Mooster, Jana
 Mechanisms of Immunodeficiency Due To NFkappaB Signaling
Defects
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 10:27:49 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9882531
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA

  
Mechanisms of immunodeficiency due to NFkappaB signaling defects 
 
 
 
A dissertation presented 
 
by 
 
Jana Lee Mooster 
 
to 
The Division of Medical Sciences 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of 
Immunology 
 
Harvard University 
Cambridge, Massachusetts 
April 2012 
   
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 Jana Lee Mooster 
All rights reserved.
   
 iii 
 
Mechanisms of immunodeficiency due to NFκB signaling defects 
 
ABSTRACT 
 
Ectodermal dysplasia with immunodeficiency (ED-ID) is a rare primary 
immunodeficiency syndrome characterized by defects in ectodermal tissues (skin, hair 
and sweat glands), recurrent infections, impaired response to Toll-like receptor ligands, 
hypogammaglobulinemia and deficient antibody production. It is caused by defective 
NFκB signaling. 
The most common form of ED-ID is X-linked. It is caused by hypomorphic 
mutations in the NFκB essential modifier gene NEMO, which is an important regulatory 
component in the NFκB signaling pathway. We report the first case of ED-ID caused by 
insufficient expression of a NEMO protein of normal sequence, due to a mutation in the 
5’ untranslated region of the NEMO gene. 
Autosomal dominant ED-ID, a rare form of ED-ID, has been reported to be 
caused by a heterozygous S32I mutation in the IκBα. This mutation prevents IκBα 
phosphorylation and inhibits its degradation. The mutant sequesters NFκB in the 
cytoplasm and acts as a dominant negative. We report the first ED-ID patient with a 
heterozygous mutation (W11X) that causes N-terminal truncation of IκBα and results in 
functional haploinsufficiency.  
We have constructed a knock-in mouse model of ED-ID caused by a 
heterozygous S32I mutation in IκBα. The mutant mice had ED, increased mortality, 
complete lack of lymph nodes and Peyer’s patches, and disorganized spleens that  
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lacked follicles, marginal zone B cells and follicular dendritic cells. T cell proliferation 
and cytokine production was normal in vitro, but in vivo contact hypersensitivity was 
severely impaired, B cell function in vitro and specific antibody response to antigens 
were severely reduced. All immune defects, except those that affected B cell function, 
were absent in IκBα S32I mutant Rag2-/- bone marrow chimeras, indicating that defects 
in non-lymphiod cells play a major role in the immunodeficiency of patients with ED-ID 
due to mutations in IκBα. This has important clinical implications, as bone marrow 
transplant may not be able to correct immune function in such patients. 
The lessons learned in these chapters may be applicable to other mutations that 
impair NFκB signaling and have important implications for the treatment of patients who 
carry these mutations. 
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Introduction: An Overview of Relevant Immune System Functions 
 
Innate and adaptive immunity 
The immune system uses two layers of defense to protect the body from 
attack by pathogens. The innate immune system launches an immediate, non-
specific response, then activates the adaptive immune system, which allows the 
body to recognize and remember specific pathogens1. The innate immune 
system includes the barrier functions of the skin and the mucosa, as well as the 
complement system and pro-inflammatory cytokine production2. Many types of 
cells in the body, from fibroblasts to macrophages, use pathogen-associated 
molecular pattern (PAMP) receptors such as the Toll-like receptors to detect 
pathogenic antigens, and send out cytokine danger signals to alert and recruit 
members of the immune system1, 2. 
 
The adaptive immune system 
The adaptive immune system recognizes antigens when they bind to T 
and B lymphocyte receptors (T cell receptor, TCR, and B cell receptor, BCR). 
Antigens are phagocytosed, processed and presented to lymphocytes by antigen 
presenting cells, such as dendritic cells. Each naïve lymphocyte bears antigen 
receptors of a single specificity. When activated, lymphocytes proliferate and 
differentiate to form a clone of effector cells3.  
 
T cells 
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 T cells recognize antigen-derived peptide that is bound to a major 
histocompatibility complex (MHC) molecule and presented on the surface of cells 
that display T cell co-stimulatory receptors. There are two major classes of T 
cells that have different functions. CD4+ T cells recognize antigen in the context 
of MHC class II molecules, and activated CD4+ T cells proliferate and produce 
cytokines that attract the appropriate immune cells to the site of infection, or help 
B cells produce specific antibodies.  CD8+ T cells recognize antigen in the 
context of MHC class I molecules which generally present peptides derived from 
intracellular antigens, and mature into cytotoxic “killer” T cells upon activation3. 
 
Immunoglobulins and B cell development 
The BCR is a cell surface bound antibody molecule, or immunoglobulin 
(Ig). B cells are an essential part of the adaptive immune system; they produce 
immunoglobulin against antigens, act as antigen presenting cells and preserve 
immunological memory by developing into memory B cells4. It is estimated that 
the human body can make up to 1011 different antibodies and B cells can make 
antibodies even to new antigens never before seen in evolution. This variability 
and adaptability is due to antigen receptor gene rearrangement, also known as 
VDJ recombination, and somatic hypermutation3. 
Immunoglobulins are made up of two protein chains, heavy and light, each 
with a variable and a constant region. The variable regions are encoded by 
several pieces, known as variable (V), diversity (D), and joining (J) segments. 
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There are multiple copies of the V, D and J gene segments, and in the bone 
marrow, each developing B cell will  
 
Figure I.1. B-cell development occurs in both the bone marrow and peripheral lymphoid tissues 
such as the spleen. In the bone marrow, development progresses through the pro-B-cell, pre-B-
cell and immature-B-cell stages. During this differentiation, rearrangements at the 
immunoglobulin locus result in the generation and surface expression of the pre-B-cell receptor 
(pre-BCR, which is comprised of an Ig heavy chain and surrogate light chains (VpreB or V5)) and 
finally a mature BCR (comprised of rearranged heavy- and light-chain genes) that is capable of 
binding antigen. At this immature stage of development, B cells undergo a selection process to 
prevent any further development of self-reactive cells. Both receptor editing and clonal deletion 
have a role at this stage. Cells successfully completing this checkpoint leave the bone marrow as 
transitional B cells, eventually maturing into mature follicular B cells (or marginal-zone B cells). 
Following an immune response, antigen-specific B cells develop into either plasma (antibody-
secreting) cells or memory B cells. From Cambier, et al7. 
 
 
assemble its immunoglobulin variable region by randomly selecting and 
combining one V, one D and one J gene segment (or one V and one J segment 
in the light chain)5, 6. The heavy chain undergoes VDJ recombination first, and it 
is expressed on the cell surface. If the heavy chain is functional, the receptor 
signals through several pathways, including the nuclear factor κB (NFκB) 
signaling pathway, inhibiting apoptosis and giving positive feedback that allows 
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the B cell to initiate light chain rearrangement. A similar checkpoint occurs after 
light chain rearrangement5 (see Figure I.1 for a depiction of B cell development 
and differentiation). T cell receptor gene rearrangement of α and β chains also 
undergoes V-J recombination to produce diverse TCRs3. 
B cells with functional surface immunoglobulin (BCR) exit the bone 
marrow and migrate to the spleen where they may encounter their antigen. 
Following activation by antigen, the B cells proliferate rapidly and the variable 
regions undergo a high rate of point mutation called somatic hypermutation. The 
daughter cells then have acquired specific amino acid differences in their BCR 
that change the affinity of the receptor. B cells that express high affinity 
immunoglobulins on their surface will receive a strong survival signal through the 
NFκB pathway, whereas those with low affinity immunoglobulins will not, and 
therefore die by apoptosis. This process is also called affinity maturation, and 
depends in part on helper T cells5. Another process that takes place after B cell 
activation is class switch recombination (CSR). The effector function of an 
antibody depends on its isotype class. Naïve B cells express only IgM and IgD, 
but in order to eliminate an antigen, IgG, IgA or IgE are necessary. Since only the 
constant region is affected, CSR allows daughter cells with the same variable 
region to produce antibodies with the same specificity but different effector 
functions6. The isotypes produced during CSR depend on the kind of cytokines 
and other signals present4, 5, 8. 
 
NFκB and the immune system 
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NFκB is a key transcription factor required for the expression of many 
important genes in immune and non-immune cells9. Receptors that result in 
NFκB activation include the BCR and TCR, PAMP receptors like the TLRs, and 
the tumor necrosis factor receptor (TNFR) and other TNFR family members 
including CD40. NFκB activation results in the synthesis of inflammatory 
cytokines and chemokines, anti-bacterial peptides, and anti-apoptotic 
molecules10. Two distinct NFκB signaling pathways have been described. The 
canonical pathway depends on the IκB kinase (IKK) complex, which contains the 
kinases IKKα and IKKβ, and the scaffolding protein IKKγ, also known as NFκB 
essential modulator (NEMO), which links receptor signaling to the IKK complex. 
The non-canonical NFκB signaling pathway is independent of NEMO and IKKβ,  
and uses the NFκB activating kinase (NIK) to link signals from surface receptors 
to IKKα. In immune cells, the canonical NFκB pathway mediates relatively rapid 
inflammatory responses to antigens and injury, whereas the non-canonical NFκB 
pathway, results in slower and more sustained NFκB signaling and is used by 
receptors that are important for the development of lymphoid organs, such as 
lymphotoxin β receptor (LTβR) which is expressed on stromal cells (see Figure 
I.2)10.  
In the canonical pathway, homodimers or heterodimers of the three Rel 
homology domain (RHD)-containing NFκB polypeptides RelA (p65), p50 and 
cRel are held in the cytoplasm at the basal state by the inhibitor of NFκB (IκB) 
proteins. These include IκBα, and IκBβ, and IκBε, with IκBα being the most 
abundant in immune cells bound predominantly to the RelA:p50 dimer. Upon 
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receptor activation, the IKK complex phosphorylates the IκB proteins at two 
conserved serine residues, S32 and S36 on IκBα, targeting it for ubiquitination, 
which is followed by its degradation in the proteasome. This releases the NFκB 
dimers and allowing them to translocate into the nucleus11. Except for dimers of 
p50, which have no transcriptional activity, all other dimers generated bind to 
specific promoters and activate transcription of genes involved in inflammation, 
cell survival, proliferation and differentiation. As a negative feedback loop for 
NFκB signaling, IκBα expression itself is also regulated by NFκB activation12, 13. 
 
 
Figure I.2. The canonical and non-canonical NFκB pathways. a. The canonical NFκB pathway is 
activated by a variety of inflammatory signals, resulting in coordinate expression of multiple 
inflammatory and innate immune genes. The proinflammatory cytokines IL-1 and TNFα activate 
NFκB, and their expression is induced in response to NFκB activation, thus forming an amplifying 
feed forward loop. b. The non-canonical pathway for NFκB, which is activated by LTβR, BAFF 
and CD40L by NIK, results in nuclear translocation of p52:RelB dimers and is strictly dependent 
on IKKα homodimers. From Bonizzi and Karin, Trends in Immunology, 200410. 
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In the non-canonical NFκB signaling pathway, the activation of the NIK-
IKKα kinase complex results in the processing of NFκB p100, which under basal 
conditions forms an inactive dimer with the NFκB protein RelB. Processing of 
p100 generates p52 and liberates the dimer. The RelB:p52 heterodimer, which 
slowly accumulates, translocates to the nucleus to activate transcription of 
chemokines, cytokines, developmental genes and other genes. There is 
additional cross-talk between the canonical and non-canonical pathways. For 
example, RelA:p50 is inhibited not only by IκB proteins, but also by a multimeric 
form of p100 called IκBδ. Furthermore, transcription of p100 and RelB, like that of 
IκBα, depend on RelA:p50 activation14.  
 
Ectodermal dysplasia with immune deficiency 
Ectodermal dysplasia (ED) with immune deficiency (ED-ID) is a rare 
primary immunodeficiency syndrome characterized by abnormal development of 
the ectoderm and severe immunologic dysfunction. Clinical features include 
those typical of ED (sparse hair, conical teeth, and reduced number of sweat 
glands) and susceptibility to severe pyogenic infections and to opportunistic 
infections with mycobacterial, fungal, and viral pathogens. Immunologic features 
include decreased cytokine production in response to Toll-like receptor (TLR) 
ligands, impaired T cell proliferation to specific antigen, variably reduced T cell 
proliferation to mitogens, and deficient specific antibody production, but normal 
numbers of T and B cells15. Normal ectodermal development requires activation 
of the canonical NFκB pathway downstream of the ectodysplasin A (EDA) 
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receptor15, 16. Similarly, effective innate and adaptive immune responses depend 
on the activation of the canonical NFκB pathway downstream of several 
receptors. These include TLRs, IL-1 receptor, TNF receptor, BCR, TCR, and 
CD409. Two forms of ED-ID have been described: an X-linked form caused by 
hypomorphic mutations in NEMO, and an autosomal dominant form caused by 
mutations in IκBα.  
Amorphic mutations in NEMO are lethal in utero. Several hypomorphic 
mutations in NEMO have been described in patients with X-linked ED-ID. There 
is some variability between patients, depending on the location of the mutation, 
but generally X-linked ED-ID patients have recurrent pyogenic infections; 
hypogammaglobulinemia with low IgG and variable IgM and IgA; specific 
antibody deficiency, particularly to polysaccharide antigens; decreased cytokine 
and type I interferon production; and a decreased response to CD4017, 18. Some 
X-linked ED-ID patients do not have ED, including one patient we followed, the 
first to be documented with decreased normal NEMO protein instead of a 
hypomorphic mutation19. This is the topic of Chapter 1. 
A handful of patients with mutations in IκBα have also been reported20-24. 
Two of these patients carry the serine 32 to isoleucine (S32I) mutation, which 
abolishes the IKK phosphorylation site. Three other patients carry mutations that 
result in premature stop codons, resulting in alternatively translated N-terminally 
truncated IκBα that is missing the S32 and S36, the sites of IKK phosphorylation. 
All of these mutations affect only one of the two IκBα alleles and impair IκBα 
degradation. This results in sequestration of NFκB, attenuating but not abolishing 
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the NFκB signal. We reported the first patient with ED-ID and a truncating 
mutation of IκBα. The patient had a W11X mutation, that resulted in the 
degradation of only of 50% of IκBα and in the activation of only 50% of NFκB 
after stimulation with IL-1 compared to normal controls22. This is the topic of 
chapter 2. 
The two patients with the S32I mutation had severe recurrent pyogenic 
infections, high IgM but low IgG and IgA levels in the serum, made no specific 
antibodies following immunization, and had an impaired T cell response to anti-
CD3. They also had a profound deficiency in memory T cells20, 21. Both patients 
received bone marrow transplantation25, 26. Only one survived, but continues to 
have impaired immune function and requires intravenous gammaglobulin 
replacement and trimethoprim/ sulfamethoxazole prophylaxis against 
opportunistic infections26. The variable presentation of ED-ID patients is likely 
due to the heterogeneity of modifier genes within the NFκB pathway as well as 
the specific mutation within the pathway.  
 
Phenotypes of NFkB knock-out mice  
Mouse models have been created where various components of the NFκB 
signaling pathway have been deleted. NFκB p50 deficient mice have impaired 
innate and adaptive immune function including increased susceptibility to some 
pathogens and selective deficiencies in class switch recombination27. RelA/p65, 
IKKβ, and NEMO knock-outs are all embryonically lethal. IKKβ and RelA/p65 
knock-out mice die from TNF-induced hepatocyte apoptosis that can be blocked 
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by crossing these mice to TNFR1 deficient mice28. However, these double knock-
out mice have increased mortality due to increased susceptibility to microbial 
infections. IκBα knock-out mice die within 7 to 10 days of birth and have severe 
inflammatory dermatitis and granulocytosis29.  
 
A mouse model of ED-ID 
The rarity of patients with ED-ID as well as logistical considerations make 
it difficult to investigate their immune function in detail. It is difficult to obtain 
samples from young children, and the therapy for treating immunodeficiency - 
intravenous immunoglobulin and bone marrow transplant - confound the baseline 
function of the patients’ immune systems. While mice do differ from humans in 
some aspects of the immune system, they are useful models for human immune 
diseases. We have created an IκBα S32I knock-in mouse model of ED-ID in 
order to gain insights into the disease.  
The IκBα S32I knock-in mutant mouse recapitulates many of the 
ectodermal and immune abnormalities found in patients with ED-ID caused by 
IκBα mutations, including poor responses to TLR stimulation and poor antibody 
responses due to an intrinsic defect in B cell function. In contrast to the ED-ID 
patients, these mice had no inherent T cell defect. However, they completely 
lacked lymph nodes (LN) and Peyer’s patches (PP), follicular dendritic cells 
(FDCs) and germinal centers (GCs). Studies of bone marrow chimeras 
generated by reconstituting Rag2-/- mice with BM from the IκBα mutant strongly 
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suggest many of these abnormalities resulted from defective NFκB signaling in 
stromal cells. The IκBα S32I knock-in mouse is the topic of Chapter 3. 
 
NFκB and lymphoid organ development 
Both canonical and non-canonical NFκB signaling plays an important role 
in the development of secondary lymphoid tissues such as LN and PP28, 30-32. 
Interaction between CD3-CD4+IL-7Rα+ lymphoid-tissue inducer (LTi) cells and 
stromal organizer cells is crucial for the development of LN and PP. LTi cells 
express LTα1β2, which engages LTβR on the stromal organizer cells33 (see 
Figure I.3). LTβR signaling causes expression of the adhesion molecules VCAM1 
and ICAM1 by activating the canonical NFκB pathway. It also induces the 
expression of the chemokines CXCL13, CCL21 and CCL19 by activating the 
non-canonical NFκB pathway34, 35. These chemokines and adhesion molecules 
attract and retain early LN-forming cells, and thus are key to LN formation and 
PP development35, 36. 
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Figure I.3. Signaling through the lymphotoxin β receptor (LTβR). From Seymour et al, 200635. 
 
Signaling by both LTβR and TNFR1, which exclusively uses the NFκB 
canonical pathway, is important for the development of follicular dendritic cells 
(FDCs) from stromal precursors in the spleen. FDCs are critical for the formation 
of B cell follicles35. Generation of FDCs requires expression of LTβR and TNFR1 
on stromal cells and expression of TNFα and LTα1β2 on lymphocytes37-39. TNF, 
TNFR1, LTα, LTβ, and LTβR deficient mice all lack FDCs and splenic follicles35, 
40. LTα, LTβ, and LTβR deficient mice and p50, p100, RelA and RelB deficient 
mice also lack marginal zones (MZs)10, 30, 40-42, since MAdCAM1 expression also 
depends on LTα1β2 and TNF activity, and is essential for proper MZ formation43, 
44. MZ B cells must require p50, since p50-/-  Rag2-/- chimeras still did not develop 
MZ B cells. This lack may be due to dysfunctional B cell receptor signaling45. 
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NFκB and the antibody response 
Immunization results in the formation of germinal centers (GCs) within 
secondary B cell follicles that serve as sites of B cell proliferation, selection, 
maturation and death during antibody responses. Disruption of NFκB signaling 
inhibits GC function, as many NFκB protein knock-out mice lack GCs10, 28. FDCs 
are also essential for the formation of GCs, since FDCs attract B cells by 
secreting chemokines, and trap immune complexes for presentation to B cells, 
engaging their BCR and switching off apoptotic machinery44, 46, 47. Formation of 
germinal centers also requires intact CD40, LPS and BCR signaling, which 
depend on NFκB as well4, 48-50. All these ligands activate NFκB via the canonical 
pathway, with CD40 also activating the non-canonical pathway. Class switch 
recombination is also reported to require NFκB27. 
 
In summary, proper antigen responses rely on the presence of FDCs and 
the formation of an intact GC. Because IκBα S32I mutant mice lack LN and PP 
and cannot form GCs, it is likely that the same is true for IκBα deficient patients, 
at least those who carry the S32I mutation. If this is indeed the case, it is unlikely 
that hematopoietic stem cell transplant would cure their immunodeficiency as 
donor-derived normal B and T cells would not be able to function without a 
proper splenic architecture, PP and LN, which depend on intact NFκB signaling 
in the recipient stromal cells. 
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ABSTRACT 
 
Background: Nuclear factor κB (NFκB) is a key transcription factor that regulates both 
innate and adaptive immunity, as well as ectodermal development.  Mutations in the 
coding region of the IκB kinase γ (IKKγ)/NFκB essential modifier (NEMO) gene cause X-
linked ectodermal dysplasia with immunodeficiency.  
Objective: To determine the genetic cause of recurrent sinopulmonary infections and 
dysgammaglobulinemia in a patient with a normal NEMO coding sequence and his 
affected brother. 
Methods: TNFα and IFNα production in response to Toll-like Receptor (TLR) 
stimulation was analyzed by ELISA, NEMO mRNA levels were measured by qPCR, and 
NEMO protein expression was measured by Western blotting.  NFκB activation was 
assessed by nuclear translocation of p65 and luciferase reporter gene assays. 
Results: TLR-induced TNFα and IFNα production by peripheral blood mononuclear 
cells was impaired in the patient and his brother. Sequencing of the patient’s NEMO 
gene revealed a novel mutation in the 5’ untranslated region, which was also present in 
the brother, resulting in abnormally spliced transcripts and a 4-fold reduction in mRNA 
levels. NEMO protein levels in EBV transformed B cells and fibroblasts from the index 
patient were 8-fold lower than normal controls. NFκB p65 nuclear translocation in the 
patient’s EBV B cells following TLR7 ligation was defective. NFκB dependent luciferase 
gene expression in IL-1 stimulated fibroblasts from the patient was impaired. 
Conclusion: This is the first description of immune deficiency resulting from low 
expression of a normal NEMO protein. 
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Clinical Implications: Immune deficiency can result from low expression of a normal 
NEMO protein. If the index of suspicion is high for defective NFκB function in an 
immune deficient patient with normal NEMO coding sequence, NEMO mRNA and 
protein levels must be analyzed and sequencing of the 5’ and 3’ regions of the NEMO 
gene should be performed. 
 
Capsule Summary: Two brothers with recurrent sinopulmonary infections were found 
to have severely reduced levels of NEMO mRNA and protein due to a mutation in the 5’ 
untranslated region of the NEMO gene. 
 
Key Words: NEMO, immune deficiency, recurrent infections, 5’ untranslated region 
mutation 
 
Abbreviations:  
EBV: Epstein-Barr virus 
ED-ID: Ectodermal dysplasia associated with immune deficiency 
ELISA: Enzyme-linked immunosorbent assay 
IκBα: Inhibitor of NFκB α 
IVIG: Intravenous immunoglobulin 
p38 MAPK: p38 mitogen activated protein kinase 
NEMO: NFκB essential modifier, also IκB kinase γ (IKKγ) 
PBMC: Peripheral blood mononuclear cell 
UTR: Untranslated region
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INTRODUCTION 
The transcription factor Nuclear Factor κB (NFκB) is required for normal 
development and function of the immune system.  Proper functioning of the immune 
system requires a tightly regulated inflammatory response, which is dependent upon 
activation of NFκB1, 2.  In the resting state, NFκB proteins are retained in the cytoplasm 
by the inhibitor of NFκB (IκB) proteins, which include IκBα.  Activation of numerous cell 
receptors, including pro-inflammatory cytokines (IL-1, TNFα), CD40, and Toll-like 
receptors, cause activation of the IκB kinase complex (IKK), which leads to 
phosphorylation of IκB proteins.  Phosphorylated IκB proteins are subsequently 
ubiquitinated and degraded, allowing nuclear translocation of NFκB and activation of 
gene transcription3, 4. 
Proper function of the IKK complex is dependent upon IκB kinase γ/NFκB 
essential modifier (IKKγ/NEMO), which is encoded by a gene (IKBKG) located on the X 
chromosome. NEMO functions as a scaffolding protein and links upstream signaling 
pathways to activation of the IKK complex3.  Numerous mutations in NEMO that result 
in the production of a dysfunctional NEMO protein have been described in male patients 
with the syndrome of ectodermal dysplasia associated with immune deficiency (ED-ID).  
ED-ID arises because normal ectodermal development (hair, teeth, and sweat glands), 
as well as effective innate and adaptive immune responses, require NEMO-dependent 
NFκB activation downstream of both the ectodysplasin A receptor (EDAR) and several 
receptors of the immune system1, 2, 5.  Mutations in NEMO that result in ED-ID are 
termed hypomorphic because they result in reduced, but not absent, function of NEMO.  
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Absence of NEMO function (amorphic mutations) in males is lethal in utero, whereas 
heterozygosity for null NEMO mutations results in incontinentia pigmenti in females6, 7. 
Impaired NFκB activation is detrimental to both innate and adaptive immune 
function. TLRs, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), 
and retinoic acid inducible gene I (RIG-I)-like helicases (RLHs) are pathogen recognition 
receptors that signal through NFκB to indicate detection of invading pathogens, 
including bacteria, mycobacteria, fungi, and viruses2, 8. Therefore, defects in NFκB 
activation can result in impaired inflammatory responses to invading pathogens, 
resulting in decreased production of pro-inflammatory cytokines and type 1 
interferons1,2.  Because T and B cell receptors also signal through NFκB, impaired 
NFκB function can result in defective antigen-specific immunity3.  As a result, patients 
with ED-ID can be susceptible to a wide variety of bacterial, mycobacterial, viral, and 
fungal infections.  Immunologic evaluation of these patients commonly reveals 
hypogammaglobulinemia with variably increased IgM and IgA levels, variable defects in 
specific antibody responses to protein and polysaccharide antigens, and variably 
impaired T cell proliferation to antigens6, 7, 9, 10. Some immunodeficient patients with 
mutations in the NEMO gene have normal ectodermal development, suggesting a less 
stringent requirement for NEMO dependent NFκB activation for normal ectodermal 
development10-13. 
 In this report, we describe an 11-year-old boy with immune deficiency but not 
ectodermal dysplasia, and a normal NEMO coding sequence but low levels of NEMO 
mRNA and protein. Sequencing of the 5’ untranslated region of the patient’s NEMO 
gene revealed a G to T mutation at position +1 of the donor splice site of the 
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untranslated exon 1B. This results in destruction of the normal exon 1B to exon 2 splice 
site, generation of two abnormally-sized NEMO mRNA species with intact coding 
sequences, reduced levels of NEMO mRNA overall, and production of 8-fold less 
NEMO protein relative to normal controls.  A brother of the patient with similar clinical 
manifestations and low NEMO expression also had an identical mutation in the 5’-
untranslated region of the NEMO gene. 
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METHODS 
 
Reagents 
Toll-like receptor ligands used in this study were as previously described14. 
Antiphospho-NFκB inhibitor α (IκBα) and antiphospho-p38 mitogen-activated protein 
kinase (MAPK) were from Cell Signaling (Danvers, MA), anti-IκBα and anti-NEMO/IKKγ 
were from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human IL-1β and 
the ELISA kits for human TNFα and human IFNα were obtained from Biosource 
(Camarillo, CA).  
Cell isolation, and stimulation 
Informed consent for blood and dermal biopsy samples was obtained from the 
patient and healthy control subjects in accord with the institutional review board at 
Children’s Hospital, Boston.  Peripheral blood mononuclear cells (PBMCs) were isolated 
by centrifugation through Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, 
Sweden). PBMCs were cultured in RPMI plus 10% FCS, with L-glutamine and 
penicillin/streptomycin (Invitrogen, Carlsbad, CA). Cell stimulations (4 x 105 
PBMCs/condition) were performed in 96-well plates in a volume of 200 µL medium with 
the following concentrations of TLR ligands: PAM3CSK4 (0.1 µg/mL), Poly I:C (50 
µg/mL), LPS (0.1 µg/mL), Flagellin (1 µg/mL), 3M-002 and 3M-013 (20 µM), and CpG 
ODN2216 (5 µM).   PBMCs were also stimulated with PMA (7.5 ng/mL) plus ionomycin 
(7.5 ng/mL), and IFNβ (1 × 105 U/mL) as positive controls.  TNFα and IFNα were 
measured after 24 hours stimulation by ELISA. 
Western blotting  
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Fibroblasts, EBV transformed B cells or PBMCs from patients and controls were 
lysed in sample buffer (62.5 mM TRIS, pH 6.8, 2% SDS, 10% glycerol, 2% b-
mercaptoethanol, 0.01% bromophenol blue).  Fibroblasts (40,000/condition) or PBMCs 
(5 × 105/condition) were stimulated with IL-1β (10 ng/ml) for the indicated times before 
lysis.  Nuclear and cytoplasmic fractions were isolated using a kit from Active Motif 
(Carlsbad, CA). Proteins were resolved by 10% SDS-PAGE (Bio-rad, Hercules, CA) and 
transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA).  Western blotting 
was performed according to the manufacturer’s recommendations.  
NEMO sequencing and expression analysis  
Sequencing of genomic DNA was performed at the Children’s Hospital Core 
facility. PCR primers and sequencing primers are available in the Supplemental 
Materials and Methods. The PCR products were cloned into the pCR2.1-TOPO vector 
(Invitrogen, Carlsbad, CA) for ease in sequencing. RNA was isolated from fibroblast 
lines or EBV lines and reverse transcribed using iScript (Bio-rad, Hercules, CA).  NEMO 
cDNA using exons 1A, 1B and 1C were amplified and cloned from cDNA isolated from 
normal fibroblasts (Supplemental Materials and Methods).  The misspliced 1B isoforms 
were amplified from cDNA isolated from patient fibroblasts.  The PCR products were 
also cloned into the pCMV-Tag4a vector (Invitrogen, Carlsbad, CA) for expression 
studies.  TaqMan gene expression assays were performed using human NEMO 
(Hs99999905_m1) and GAPDH (Hs00175318_m1) probes from Applied Biosystems 
(Roche, Branchburg, NJ). 
NFκB reporter assays 
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NFκB-luciferase reporter plasmids containing four NFκB binding sites in the 
promoter, and Renilla control plasmids were both kindly provided by Dr. Laurie 
Glimcher, Harvard Medical School, Boston, MA. The plasmids were transfected into 
patient and normal fibroblasts using Lipofectamine LTX with Plus reagent (Invitrogen, 
Carlsbad, CA). After 24 hours, the cells were stimulated for 6 hours with 10-15 ng/ml 
recombinant IL-1β.  The cells were lysed in passive lysis buffer and luciferase activity 
was analyzed using the Dual Luciferase Reporter Assay System (Promega, Madison, 
WI).  
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SUPPLEMENTAL MATERIALS AND METHODS 
 
Primer pairs used to amplify NEMO coding region cDNA for sequencing, including the 3’ 
UTR: 
 
Forward Reverse 
TCACCAAACTTGACTGCGCTCT CCAGAGCCTGGCATTCCTTAG 
AGGACAAGGCCTCTGTGAAA GACAGCTGGCCTTCAGTTTGC 
GCCGAGCAGCACAAGATT GGAGAGGAAAGCGCAGACT 
 
Primer pairs used for 5’ upstream genomic PCR for sequencing: 
 
Forward Reverse 
AACGGATACTACTCAGCAACACTG CTGGAAGGGGGCAGTAAGTAC 
CCAGAAATGTTCTGAGGAAAGG CGTGTAATTTGAGATGAAGCCCTT 
CGCACGATGTGGAAGAACTAACTA AGACAACATCTGCCTATCGTCA 
TTTCTACTCCTCCCTCCTCCTC GAAGAGCCAACTGTGTGAGATGG 
 
 
Sequencing primers for 5’ upstream genomic sequencing: 
 
GGAGTCTCACTCTGTCGGCC  CATGGTGAGACCCCGTTTC 
GCCAGGCAGTTAGGAAGC  GACTGGTCTGCTGAGTCAC 
CACAAGGTGACTTAGTAGA  CCATCATTGGGATGCGTCC 
CTAGGTCATGCTGAGCTTGT  CGAGGCTCTTCAGAGAGAGG 
TCAGAGTCCTGGCTGTTAAG  AGTGCTGGGATTACAGACGT 
CTCTTCTGAGGGGACCAG  AGTCTCACTGCCCCATGG 
GGTGGCTCATGCCTGTCA  CCCATGATGATGAATATGTG 
CCTGGAGCATGGGAGATG  TGCTCTGCATCCCCAATT 
CCCACAGCTATGACACCG  ATCGTTCTAGCAGTGGTGG 
CATTCACAGCTACCAACTTC  CTCACCGCAACCTCCATC 
GTGGATTTGCCTGTTGTAGA  ATGGATTCGCCATCAGCT 
CGTGTCACCACACTCTGC  GGAGACTAGAAGTCCAAAACC 
TTCCAGCCTGGAGCTAGG 
 
 
Primers for cDNA transcript PCR (adds BamHI site in forward primers and HindIII site 
on reverse): 
Exon 1A Forward: 5’ ATGGATCCCATGGCCCTTGTGATCCAG 3’ 
Exon 1B Forward: 5’ ATGGATCCGACACCGGAAGCCGGAAG 3’ 
Exon 1C Forward: 5’ ATGGATCCAGCCCGTTCCTGCTCCG 3’ 
Exon 10 Reverse: 5’ ATAAGCTTCTCAATGCACTCCATGACATGTATC 3’
 34 
RESULTS 
 
Case Report 
The index patient is an 11-year-old boy who was healthy until three years of age 
when he began experiencing recurrent upper and lower respiratory infections (otitis 
requiring placement of tympanostomy tubes, lymphadenitis, 
bronchitis/bronchopneumonia), recurrent diarrhea and hematuria.  Causative pathogens 
for the diarrhea and hematuria were not identified and these conditions have resolved.  
A chest CT scan revealed bronchiectasis.  There was no hepatosplenomegaly.  The 
patient has no features of ectodermal dysplasia (Fig. 1.1).  His immune evaluation at 4 
years of age revealed normal total white blood count, lymphocyte count and normal T 
and B cell subsets, but a low percentage of CD27+IgD-IgM- switched memory B cells  
(Table 1.1).  The patient had an elevated IgA level (901 mg/dl) with normal IgG (653 
mg/dl) and low IgM (31mg/dl).  IgM levels have remained low (Table 1.2).  Specific 
antibodies against tetanus toxoid, rubella, and pneumococccal polysaccharide antigens 
were detected, but the patient had rapidly waning antibody titers to tetanus and 
pneumococcus over time.  There was no specific antibody response to hepatitis B virus, 
measles or mumps immunization (Table 1.3).  He had normal in vitro T cell proliferation 
responses to phytohemagglutinin (PHA), pokeweed mitogen (PWM), and anti-CD3, but 
decreased responses to tetanus toxoid antigen (Table 1.4).  The patient was started on 
intravenous immunoglobulin (IVIG) therapy at the age of 10 years.  He is currently 
healthy, with improved and stable pulmonary status and no active gastrointestinal 
complaints.  The patient’s younger brother, age 5, also suffered from recurrent  
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Figure 1.1 Normal ectodermal development in the patient. The index patient at 11 years of age.  Notice 
normal dentition and hairline.
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Table 1.1.  Lymphocyte counts of the index patient 
 
Cell counts per mm3 11/2001 Normal range  
Absolute lymphocyte count  5140 1700-6900 
CD3 3084 900-4500 
CD4 596 500-2400 
CD8 709 300-1600 
CD16/CD56 1182 100-1000 
CD19 668 200-2100 
     CD27+IgD+IgM+ (non-switched memory) 29 (4.4% of CD19+) 30-98 (7-14%) 
     CD27+IgD-IgM- (switched memory) 10 (1.5% of CD19+) 22-76 (5-
12.3%) 
     CD27-IgD+IgM+ (naive) 625 (93.6% of 
CD19+) 
260-716 (70.7-
85%) 
 
These measurements were taken when the patient was first seen at 4 years of age. Similar 
numbers have been obtained on subsequent evaluations. 
 
Reference range values (10th-90th percentile) for B cell subsets: 
Huck K, Feyen O, Ghosh S, Beltz K, Bellert S, Niehues T. Memory B-cells in healthy and 
antibody-deficient children.  Clin Immunol. 2009; 131:50-9.  
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Table 1.2.  Serum Immunoglobulin levels from the index patient 
 
Serum Immunoglobulins (mg/dL) 11/2001 Normal range 
IgG 653 441-1135 
IgG1 369 360-810 
IgG2 248 60-310 
IgG3 38 9-160 
IgG4 8 9-160 
IgA 901 22-159 
IgM 31 47-200 
 
This table shows immunoglobulin levels measured when the patient was first seen at age 4, 
before intravenous immunoglobulin therapy was initiated. 
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Table 1.3. Antibody response to immunization 
 
Serum Titers 6/2003 5/2004 1/2005 9/2006 6/2008 
Tetanus (IU/mL) 0.2 - - 0.09 0.1 
Measles (IU/mL) - absent - absent absent 
Mumps (AU/mL)  absent  absent absent 
Pneumococcus (mg/L) 40  150 90 30 
Hepatitis B Virus sAb 
(mIU/mL) 
- absent - absent absent 
 
The patient received MMR vaccinations 8/1999 and 9/2005, Tetanus 7/1998, 9/1998, 3/1999, 
8/1999, 6/2003, and 12/2005, Pneumococcus (Pneumovax) 6/2003 and 12/2005, Hepatitis B 
Virus 7/1998, 9/1998, 3/1999 and 3/2007. Protective titers after immunization with tetanus 
toxoid and pneumococcus are >0.1 IU/mL and >60 mg/L, respectively.  
 
 39 
Table 1.4.  Proliferation of PBMCs, 3H counts per minute 
 
Stimulus Patient  Healthy Control 
Medium, day 3 455 316 
PHA 33376 34506 
PWM 25564 36794 
Anti-CD3 (OKT3) 25267 34111 
Medium, day 6 282 187 
Tetanus 2165 9601 
 
Measured 5/2006, blood sample was taken before IVIG infusion. Cells were examined for 
proliferation to PHA, PWM and anti-CD3 after 3 days of culture, and to tetanus after 6 days of 
culture. 
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respiratory infections, and had no features of ectodermal dysplasia. His immunologic 
analysis revealed normal lymphocyte counts, normal T cell subset distribution, 
decreased percentage of CD27+IgD-IgM- switched memory B cells (3.8% of CD19+ 
cells, normal 10th to 90th percentile range 5-12.3%), an IgG of 653 mg/dL (normal range 
441-1135 mg/dL), an IgA of 65 mg/dL (normal range 22-159 mg/dL), a borderline IgM of 
47 mg/dL (normal range 47-200 mg/dL), and failure to respond to immunization with 
pneumococcus vaccine (pre-immunization titer 3 mg/L, post immunization titer 3 mg/L, 
normal response >60 mg/L). 
Family history is also significant for an older male maternal cousin of the patient 
who presented with recurrent upper respiratory infections (pharyngitis, tonsillitis) and 
hypogammaglobulinemia from early childhood. He did not have ectodermal dysplasia 
and was diagnosed with common variable immune deficiency. In his late teens he was 
diagnosed with widespread Mycobacterium avium intracellulare infection, and had 
multiple pneumonias, chronic diarrhea, and malnutrition. He died of infection at the age 
of 19 years.  
Impaired cytokine production in response to TLR ligands 
The index patient’s history of recurrent infections, low IgM, elevated IgA, and a 
family history of a maternal cousin with recurrent infections, including infection with a 
poorly virulent mycobacterium, was consistent with impaired NFκB activation due to a 
defect in NEMO.  To test NFκB function, we measured cytokine production by 
peripheral blood mononuclear cells (PBMCs) in response to TLR ligands. Stimulation of 
the index patient’s PBMCs with PAM3CSK4 (TLR1,2), polyI:C (TLR3), LPS (TLR4),
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Figure 1.2. Impaired TLR-induced NFκB–dependent cytokine production by patient PBMCs.  
PBMCs were incubated with medium or TLR ligands for 24 hours and (A) TNFα and (B) IFNα 
were quantified. Graphs show the mean and SD of 4 independent experiments using PBMCs 
from the index patient and healthy controls (n=4).  *p<0.05, ***p<0.001.   (C) TNFα production in 
PBMCs from the patient’s affected brother.  
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flagellin (TLR5), 3M-013 (TLR7), 3M-002 (TLR8), and ODN2216 (TLR9) revealed 
significant impairment of TNFα production compared to the mean of 4 normal 
healthy controls (Fig. 1.2A).  Stimulation of the index patient’s PBMCs with TLR3 
and 9 ligands also revealed significant impairment of IFNα production compared 
to the mean of 4 normal healthy controls (Fig. 1.2B). TLR-induced TNFα 
production by the patient’s affected younger brother was similarly impaired (Fig. 
1.2C).  In contrast, TLR-induced cytokine production in PBMCS from the patient’s 
mother was normal (Fig. 1.2C). Studies on the mother and brother of the index 
patient were performed only once due to limited availability of blood from them.  
Technical reasons precluded measurement of IFNα production in response to 
TLR stimulation of their PBMCs. 
Levels of NEMO protein and mRNA are significantly decreased in the 
patient 
Impaired TLR functions in the patient and his brother are consistent with a 
defect in IKKγ/NEMO.  A Western blot of lysates of PBMCs from the patient and 
his brother showed severely reduced NEMO protein levels compared to a normal 
control (Fig. 1.3A).  In contrast, the NEMO protein level in the mother’s PBMCs 
was comparable to that of the normal control. Decreased NEMO protein levels in 
the patient were confirmed by comparing NEMO levels in lysates from EBV 
transformed B cells from the patient and five healthy controls (Fig. 1.3B).  
Scanning densitometry revealed an 8-fold decrease in relative NEMO protein 
levels (normalized to actin) compared to the mean of five normal controls (Fig. 
1.3C).  
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Figure 1.3.  Decreased NEMO protein and mRNA levels in the patient. Western blots from (A) 
PBMC lysates from control, index patient, affected brother, and unaffected mother, (B) EBV B cell 
lysates. (C) Scanning densitometry of NEMO protein levels for each EBV B cell line, normalized 
to actin. Controls arbitrarily set to 1. (D) qPCR analysis of NEMO mRNA levels, normalized to 
GAPDH, in EBV B cell lines from index patient, brother, and 8 controls. Bar represents the mean, 
dashed lines span the 95% confidence interval. 
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This decrease was confirmed in fibroblasts from the index patient, which exhibited an 8-
fold decrease in NEMO protein levels compared to the mean of fibroblasts from 4 
normal controls (data not shown).  
Given the reduced NEMO protein levels in the patient and his brother, cDNA was 
generated from patient fibroblasts and sequenced.  No mutations were found within the 
coding region.  NEMO mRNA levels were then quantified by qPCR in EBV B cells from 
the patient, his brother, and 8 normal controls. GAPDH mRNA levels were used as an 
internal control. The patient’s and his brother’s EBV transformed B cell lines had 4-5 
fold lower NEMO mRNA levels than EBV B cell lines from healthy controls (Fig. 1.3D).   
Sequencing reveals a splice site mutation in the 5’ untranslated region of the 
patient’s NEMO gene 
Since NEMO mRNA levels were significantly decreased in the patient, the 5’ and 
3’ untranslated (UTR) regions of his NEMO gene were analyzed.  No mutations were 
detected in the 3’UTR, or in the polyA tail signal region.  The four first exons (1A-D) of 
the NEMO gene are alternatively spliced to the ATG-containing second exon, resulting 
in mRNAs that are translated into an identical protein product (Fig. 1.4A).  Lymphocytes 
express NEMO transcripts containing exons 1A, 1B and 1C, but not 1D, spliced to exon 
2.  Exon 1B transcripts are much more abundant than transcripts starting at exon 1A or 
exon 1C15. We found a similar pattern in normal fibroblasts (data not shown).  We 
sequenced an approximately 20 Kb region of genomic DNA upstream of the NEMO 
translation initiation site, including exons 1A, 1B, 1C and 1D.  Two previously described 
polymorphisms were found in the intron between exon 1A and 1B (-4875 bp and -4858 
bp from the translation initiation site).  A novel G to T mutation was found 4257 bp 
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upstream of the translation initiation site, at position +1 of the donor splice-site of exon 
1B (Fig. 1.4A). This mutation destroys the normal exon 1B to exon 2 splice site. The 
mutation was present in the patient’s affected younger brother. The patient’s mother 
and maternal aunt were confirmed to be carriers.  
The splice site mutation results in two alternatively spliced mRNA products in the 
patient 
The splice site mutation in the patient and his brother would be expected to result 
in aberrant splicing. To test this hypothesis, we amplified the three potential PCR 
products arising from the splicing of exons 1A, 1B and 1C to exon 2. Oligonucleotides 
corresponding to the extreme 18 bp at the 5’ end of each of exons 1A, 1B and 1C were 
used as forward primers. The common reverse primer corresponded to the last 25 bp 
before the stop codon in exon 10 (Fig. 1.4A). Transcripts from exon 1D are liver-
specific15 and were not analyzed. PCR products were amplified from cDNA isolated 
from EBV B cell lines from the patient and a healthy control.  When the exon 1A and 1C 
specific primers were used, both patient and control template cDNA produced the 
normally sized transcripts (Fig. 1.4B). When the exon 1B specific primer was used, a 
normally sized exon 1B-containing transcript of 1404 bp was amplified from the control 
cDNA.  However, the patient cDNA instead gave rise to two aberrantly spliced 
transcripts 1748 bp and 1294 bp in size respectively (Fig. 1.4B).  The larger 1748 bp 
transcript starts at exon 1B, reads through the 1B-1C intron and exon 1C, then splices 
to exon 2.  The smaller 1294 bp transcript uses an alternative splice site within exon 1B 
that splices to exon 2, resulting in an mRNA product with an internal deletion (Fig. 
1.4C).  Similar results were obtained using cDNA from fibroblasts (data not shown). 
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Figure 1.4. The patients’ NEMO mutation results in two aberrant mRNA products. (A) Representation of 
normal NEMO splicing. Patient’s mutation shown as asterisk. mRNA splicing using exon 1A, 1B or 1C is 
depicted, arrows represent PCR primers used. (B) Agarose gel showing control and patient NEMO RT-
PCR products containing exons 1A, 1C and 1B. (C) Schematic of aberrant NEMO exon 1B transcripts in 
the patient. 
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Figure 1.5 Western blot showing expression of NEMO cDNA isoforms amplified from normal and patient 
cells. NEMO cDNA using exons 1B and 1C were amplified from cDNA isolated from normal fibroblasts 
and the misspliced 1B isoforms were amplified from cDNA isolated from patient fibroblasts.  The PCR 
products were cloned into the pCMV-Tag4a vector and expressed in T293 HEK cells (top) or in Nemo-/- 
mouse embryonic fibroblasts (bottom). Note the presence of the endogenous NEMO band in T293 cells 
but not in NEMO deficient MEFs.
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Introduction in 293 T cells and NEMO-/- mouse embryonic fibroblasts of constructs that 
encoded cDNA corresponding to the 1748 bp and 1294 bp transcripts under the control 
of the pCMV promoter resulted in the expression of normal sized NEMO protein Fig. 
1.5), demonstrating that these transcripts were potentially translated in the patient’s 
cells. 
 
Impaired phosphorylation and degradation of IκBα  in response to IL-1 and 
reduced NFκB activation in patient cells 
To assess the level of impairment of NFκB signaling, primary fibroblasts from the 
patient were treated with IL-1β and IκBα phosphorylation and degradation were 
analyzed by Western blot (Fig. 1.6A). In normal fibroblasts, the majority of IκBα protein 
was phosphorylated after 5 minutes of IL-1β stimulation and IκBα protein was 
completely degraded by 15 minutes. In contrast, in the patient’s fibroblasts, only about 
half of the IκBα was phosphorylated after 5 minutes of IL-1β stimulation and there was 
still residual IκBα protein detected 15 and 30 minutes after stimulation.  Western blotting 
with anti-phospho-p38 MAPK demonstrates a comparable response of normal and 
patient fibroblasts to IL-1β stimulation.  
Incomplete IκBα degradation in response to receptor stimulation would lead to 
reduced NFκB nuclear translocation. To assess NFκB nuclear translocation, patient and 
control EBV B cell lines were stimulated with the TLR7 ligand 3M-013, and nuclear 
extracts were prepared 30, 60 and 90 minutes after stimulation and Western blotted 
with an anti-p65 antibody. Western blot with anti-PARP was used as a protein loading 
control for nuclear extracts. The results demonstrated reduced p65 nuclear 
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translocation in the patient EBV cells in response to stimulation with TLR7 ligand (Fig. 
1.6B).  
In order to measure NFκB activity, NFκB luciferase assays were performed on 
normal and patient fibroblasts.  Fibroblasts were transfected with NFκB luciferase 
reporter plasmids and control Renilla plasmids.  Cells were lysed following a 6-hour 
stimulation with IL-1β.  Patient fibroblasts had 2.4 times less NFκB activity following IL-
1β stimulation compared to control fibroblasts, p = 0.0126 (Fig. 1.6C).  
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Figure 1.6. NFκB signaling is reduced in the patient. (A) WB of lysates from fibroblasts stimulated with IL-
1β. (B) Western blot of p65 nuclear translocation in TLR7 stimulated EBV B cells. (C) NFκB-luciferase 
reporter assay in fibroblasts treated 6 hours with IL-1β. Fold activation represents mean and SD of 8 
experiments using patient fibroblasts and three healthy controls. 
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DISCUSSION 
We present a male patient with immunodeficiency without ectodermal dysplasia 
associated with a novel splice site mutation in the 5’UTR of the NEMO transcript.  This 
mutation results in abnormally spliced NEMO mRNA species, a 4-fold decreased level 
of NEMO mRNA levels and an 8-fold lower expression level of NEMO protein than in 
normal controls.  To our knowledge, this is the first description of an immunodeficiency 
due to inadequate levels of a normal NEMO protein, as opposed to a mutation that 
results in an altered protein with hypomorphic function.   
The low NEMO protein levels in the patient lead to reduced IκBα phosphorylation 
and degradation, resulting in decreased NFκB function after IL-1 stimulation.  Although 
the reduced NEMO expression and reduced NFκB activation allowed normal 
ectodermal development, they resulted in impaired innate and adaptive immune 
functions, including low IgM and high IgA, typical of patients with hypomorphic NEMO 
mutations10, 16. Antibody production to protein and polysaccharide antigens was variably 
impaired. Importantly, specific antibody titers waned rapidly over time. B and T cell total 
numbers were normal, although the absolute number of memory B cells was low. The 
patient’s younger brother is also affected and has the same NEMO mutation.  
Additionally, a male cousin of the patient had recurrent infections and died from atypical 
mycobacterial pneumonia. Although his NEMO gene was never sequenced, his mother 
(the patient’s maternal aunt) is a carrier of the mutation in the 5’UTR of NEMO. Thus, 
most likely he had the same mutation as the index patient and suffered from NEMO 
deficiency. 
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The mutation in the 5’UTR of NEMO that we have described is unique because it 
results in the generation of abnormally sized NEMO message, with low total NEMO 
mRNA, resulting in protein levels significantly lower than normal controls.  Importantly, 
the reduction in NEMO protein levels appears greater than the reduction in the level of 
NEMO message, suggesting that translation of the abnormally sized NEMO message 
may be relatively inefficient.  The reduction in NEMO protein expression was associated 
with a 2.4-fold (60%) reduction in NFκB activation, as measured by luciferase assay.  
This case demonstrates that a residual NFκB activity of ~40% might be sufficient for 
ectodermal development; however, it results in both innate and adaptive immune 
dysfunction. This is consistent with the notion that immune function has a more stringent 
requirement for NFκB function than does ectodermal development.  We have 
demonstrated that NEMO expression is low in ectodermally-derived cells (e.g. 
fibroblasts) and mesenchymally-derived cells (e.g. PBMCs and EBV transformed B 
cells) in our index patient.  However, it is presently not known which NEMO transcripts 
are used during ectodermal development.  It remains possible that other isoforms may 
be utilized, that would circumvent the aberrant 1B transcripts and allow normal 
ectodermal development. 
The 8-fold reduction in expression of a normal NEMO protein resulted in a 
reproducible, modestly reduced degradation of IκBα in IL-1 stimulated fibroblasts, likely 
due to inefficient activation of the IKK complex, relative to normal fibroblasts (Fig. 1.4A).  
The modestly reduced degradation of IκBα, however, resulted in significant impairment 
in TLR induced TNFα production (Fig. 1.1).  Although we did not examine the effects of 
reduced NEMO expression on IL-1 induced degradation of IκBβ and IκBε, degradation 
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of these inhibitors of NFκB would be expected to be similarly impaired.  Therefore, the 
effect of reduced NEMO expression on NFκB-dependent functions would be due to 
impaired disinhibition of IκBα, IκBβ, and IκBε. 
The case we present indicates that in male patients with dysgammaglobulinemia 
and recurrent sinopulmonary infections, but with normal ectodermal development and a 
normal NEMO coding sequence, evaluation of NEMO mRNA and protein levels and of 
NFκB-dependent immune responses (e.g. TLR function) is essential.  Abnormal 
expression of NEMO should then be followed by analysis of the 5’ and 3’ untranslated 
regions. 
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Clinical Immunology, Volume 120, 2007 and has been reproduced with 
permission.
 58 
 
 
 
 
 
 
 
Note of Clarification: 
This chapter was a collaboration between myself and Douglas McDonald. I 
performed the Western blots and inhibition experiments. 
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ABSTRACT 
 
Background: Nuclear factor κB (NFκB) is a master transcriptional regulator 
critical for ectodermal development and normal innate and adaptive immune 
function. Mutations in the IκB kinase γ/NFκB essential modifier have been 
described in male subjects with the syndrome of X-linked ectodermal dysplasia 
with immune deficiency that results from impaired activation of NFκB. 
Objectives: We sought to determine the genetic cause of ectodermal dysplasia 
with immune deficiency in a female patient. 
Methods: Toll-like receptor-induced production of the NFκB-dependent 
cytokines TNFα and IFNα was examined by means of ELISA, the patient’s IκBα 
gene was sequenced, and NFκB activation was evaluated by means of 
electrophoretic mobility shift assay and NFκB–luciferase assays in transfectants. 
Results: Toll-like receptor function was impaired in the patient. Sequencing of 
the patient’s IκBα gene revealed a novel heterozygous mutation at amino acid 11 
(W11X). The mutant IkBaW11X protein did not undergo ligand-induced 
phosphorylation or degradation and retained NFκB in the cytoplasm. This led to 
roughly a 50% decrease in NFκB DNA-binding activity, leading to functional 
haploinsufficiency of NFκB activation. Unlike the only other reported IκBα mutant 
associated with ectodermal dysplasia associated with immune deficiency (ED-
ID), S32I, IκBαW11X exerted no dominant-negative effect.  
Conclusions: Functional NFκB haploinsufficiency was associated with ED-ID, 
and this strongly suggests that normal ectodermal development and immune 
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function are stringently dependent on NFκB in that they might require more than 
half of normal NFκB activity. 
Clinical implications: Although ED-ID is well described in male subjects, female 
subjects can present with a similar syndrome of ectodermal dysplasia with 
immune deficiency resulting from mutations in autosomal genes within the NFκB 
pathway.
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INTRODUCTION 
 
Nuclear factor of kappa B (NFκB) is a master transcription factor required 
for the normal development and function of the immune system.  Effective host 
defense against invading pathogens requires an effective inflammatory response 
that is dependent upon appropriate activation of NFκB.  Five NFκB proteins have 
been described, including p65 (RelA), p105/p50, p100/p52, c-Rel, and RelB1, 2. 
The NFκB proteins form numerous homo- and heterodimers that mediate specific 
biological responses. In resting cells, NFκB proteins are retained in the 
cytoplasm by the IκB (inhibitor of NFκB) family of proteins, which includes IκBα, 
IκBβ, and IκBε3.  The prototypic IκB, IκBα, is abundant in white blood cells.  
Activation of a wide variety of cell surface receptors results in NFκB activation.  
Stimuli including proinflammatory cytokines (TNFα and IL-1) and pathogen 
associated molecular patterns (i.e. Toll-like receptor ligands) cause activation of 
the IκB kinase (IKK) complex, which phosphorylates IκBα on serine residues 32 
and 36, leading to ubiquitination of lysines 21 and 22 and the subsequent 
degradation of IκBα4. Serines 32 and 36 as well as lysines 21 and 22 are 
contained within an N-terminal 73-amino-acid sequence designated the signal 
response domain because this region regulates the degradation of IκBα. 
Inflammation-induced degradation of IκBα releases NFκB, primarily p50/p65 
heterodimers, uncovering a nuclear localization signal that allows NFκB to 
translocate to the nucleus where it binds to consensus sequences in the 
promoters of a wide variety of genes and results in their transcription2.  
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Importantly, transcription of IκBα is regulated by NFκB5, 6. In this manner, NFκB-
induced transcription of IκBα leads to a feedback inhibition of NFκB activity. 
To date, mutations in two genes, IκB kinase γ/NFκB essential modifer 
(IKKγ/NEMO) and IκBα, have been found to result in impaired activation of NFκB 
in human subjects and in ectodermal dysplasia associated with immune 
deficiency (ED-ID)7. This combination of clinical manifestations arises because 
normal ectodermal development (hair, teeth, and sweat glands), as well as 
effective innate and adaptive immune responses, depends on NFκB activation8.  
IKKγ/NEMO is the scaffolding subunit of the IKK complex that links upstream 
receptor signaling components to the protein kinases IKKα and IKKβ3. Because 
IKKγ/NEMO is encoded on the X chromosome, IKKγ/NEMO deficiency affects 
only boys who suffer from X-linked ED-ID. Numerous mutations in IKKγ/NEMO 
have been described9. They are all hypomorphic, because total loss of IKK 
activity and, therefore, of NFκB activity is lethal.  A single mutation in one of the 
two IκBα alleles has been identified to date as a cause of autosomal dominant 
ED-ID in two male patients10, 11. The mutation substitutes Ser32 with isoleucine 
(S32I). Since Ser32 is one of the two serines phosphorylated by IKKβ, IκBαS32I 
cannot be phosphorylated nor degraded, resulting in impaired NFκB activation.  
The IκBαS32I mutation was termed a hypermorphic mutation, since IκBαS32I 
cannot be “disinhibited” and thereby exaggerates its function. In addition, the 
IκBαS32I mutant was shown to exert a dominant-negative effect because the 
IκBαS32I mutant was a significantly more potent inhibitor of NFκB activity than 
WT IκBα in an NFκB luciferase reporter assay10. 
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Impaired activation of NFκB has deleterious effects on both innate and 
adaptive immune function12. TLRs and nucleotide-binding oligomerization domain 
(NOD) proteins are pathogen recognition receptors within the innate immune 
system that detect invading pathogens, including bacteria, mycobacteria, fungi, 
and viruses13, 14. Because TLRs and NOD proteins signal through NFκB, defects 
in NFκB activation can cause impaired inflammatory responses to invading 
pathogens, resulting in decreased production of proinflammatory cytokines and 
type I interferons7, 15, 16.  Since the T cell receptor and B cell receptor signaling 
pathways also converge on NFκB, impaired NFκB function leads to deficits in 
antigen specific immunity17.  As a result, patients with X-linked ED-ID 
demonstrate increased susceptibility to a wide variety of bacterial, mycobacterial, 
fungal, and viral infections18. Analysis of immunoglobulins in these patients 
commonly reveals hypogammaglobulinemia with variably elevated IgM or IgA 
levels. Specific antibody responses to protein and polysaccharide antigens are 
variably impaired.  T cell proliferation to mitogens (phytohemagglutinin, 
pokeweed mitogen, concanavalin A) is intact; however, T cell proliferation to 
antigens is variably diminished18. 
Two boys with ED-ID but normal sequence of IKKγ/NEMO have been 
found to have a heterozygous IκBαS32I mutation. In both patients, bone marrow 
transplantation was performed within 1 to 3 years of life due to severe, recurrent 
infections. Immunologic analysis revealed highly elevated serum IgM levels, low 
levels of serum IgG and IgA levels and absent specific antibody titers. Cellular 
analysis revealed normal percentages of B and T lymphocytes; however, there 
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was a polyclonal lymphocytosis and an absence of memory T cells. T cell 
proliferation to mitogens (PHA) was normal; however T cell proliferation to 
antigens (candida, tetanus) was absent. The IκBαS32I mutation was shown to 
prevent ligand-induced phosphorylation of IκBα, and its subsequent degradation.  
NFκB activation was severely impaired in the patient’s cells and the mutant was 
shown to exert a dominant negative effect.   
In this report we describe a ten-year-old female with ED-ID and a novel 
heterozygous nonsense mutation in IκBα (IκBαW11X), resulting in a persistence-
of-function mutant that cannot be degraded. Unlike IκBαS32I, the only previously 
described human IκBα mutant associated with ED-ID, IκBαW11X does not exert 
a dominant negative effect and results in functional NFκB haploinsufficiency. The 
association of ED-ID with the IκBαW11X mutant suggests a stringent 
requirement for NFκB activation in ectodermal development and immune 
function. 
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MATERIALS and METHODS 
Production of cytokines in response to TLR ligands   
Informed consent for blood and dermal biopsy samples was obtained from 
the patient and heatlthy control subjects in accord with with institutional review 
board at Children’s Hospital Boston. PBMCs were obtained by means of 
centrifugation through Ficoll-Paque PLUS (Ammersham Biosciences). PBMCs 
(300,000 cells/200 µl) were stimulated in media, as previously described19. Cell 
stimulations were 12 hours for TNFα ELISA and 48 hours for IFNα ELISA 
(Invitrogen). 
Sequencing of IκBα   
RNA was isolated from PBMCs as previously described19.  cDNA was 
generated random-primed reverse transcription using Superscript II (Invitrogen).  
The IκBα transcript was amplified using the forward primer 5’-
CCAGCGAGGAAGCAGCG-3’ and the reverse primer 5’-
CTAGGCAGTGTGCAGTGTGG-3’ with an annealing temperature of 61oC.  The 
internal forward primer 5-CATCCTGAAGGCTACCAACTAC-3’ and the reverse 
primer 5’-GAGGCTAAGTGTAGACACG-5’ were also used for sequencing.  
Genomic DNA was generated from the patient’s fibroblasts using the 
phenol:chloroform method.  Exon 1 of IκBα was sequenced using the forward 
primer 5’-GCAGAGGACGAAGCCAGTTC-3’ and reverse primer 5’-
CCACTTACGAGTCCCGTC-3’. Sequencing of IκBα was performed at the 
Molecular Biology Core Facility at Children’s Hospital, Boston. 
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Western blotting   
Primary dermal fibroblast cultures were grown in RPMI media plus 10% 
fetal calf serum (Hyclone, Logan UT) plus L-glutamine and penicillin and 
streptomycin (Invitrogen, Carlsbad, CA).  Fibroblasts were stimulated with media 
or 25 ng/ml IL-1 (Invitrogen, Carlsbad, CA) for the indicated times, followed by 
lysis in Sample buffer (62.5 mmol/l TRIS, pH 6.8, 2% wt./vol. SDS, 10% glycerol, 
2% β-mercaptoethanol, 0.01% bromophenol blue).  Lysates were resolved by 
12% SDS-PAGE (BioRad, Hercules, CA) and proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes (Milipore, Billerica, MA).  Western 
blotting was performed with anti-phospho-IκBα (Cell Signaling, Danvers, MA), 
anti-full length (FL) IκBα (Upstate, Charlottsville, VA), anti-N-terminal IκBα 
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho- p38MAPK and anti-
p38MAPK (Cell Signaling, Danvers, MA), and anti-p65  (Santa Cruz 
Biotechnology) according to manufacturer recommendations.  Sheep anti-mouse 
HRP conjugated and sheep anti-rabbit HRP conjugated secondary antibodies 
were obtained from GE Healthcare (Piscataway, NJ). 
Immunoprecipitation  
Fibroblasts or HEK293T cells were lysed in 1 ml Triton buffer (20 mM 
TRIS pH 7.4, 1% Triton X-100 (Sigma, St. Louis, MO.), 100 mM NaCl, 10 mM 
NaF, 2 mM sodium orthovanadate, 1 mM EGTA, protease inhibitor cocktail 
(Sigma, St. Louis, MO.).  Lysates were incubated at 4oC for 3 hours with 1 µg 
anti-FL-IκBα, anti-Flag (Sigma, St. Louis, MO), or non specific antibody (Ctrl IgG) 
and protein G-Sepharose (Calbiochem, La Jolla, CA).  Immunopreciptates were 
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washed three times in 1 ml Triton buffer, followed by boiling in Sample buffer.  
Immunoprecipitates were resolved by SDS-PAGE as above.   
Electrophoretic mobility shift assay   
Equal numbers of primary fibroblasts were removed from flasks by 
trypsinization and plated in 6 well tissue culture plates.  Fibroblasts were 
stimulated with 25 ng/ml IL-1 over a 1-hour time course.  Media was removed 
and cells were scraped off in 1 ml ice cold PBS plus phosphatase inhibitors 
(Active Motif, Carlsbad, CA).  Cytosolic and nuclear fractions were generated 
using a nuclear extract kit (Active Motif).  Protein content was measured using 
Bradford reagent (Pierce, Rockford, IL).  EMSA for NFκB was performed as 
previously described20 using the oligonucleotide 5’-
TCGCTGGGGACTTTCCAGGGA-3’ and 2 µg of nuclear extract per condition.  
Supershift of NFκB complexes was performed using anti-p65 antibodies (Santa 
Cruz Biotechnology) included in one sample to demonstrate the specificity of the 
probe.  In addition, Western blot with anti-PARP (Santa Cruz Biotechnology) and 
anti-p50 (Santa Cruz Biotechnology) was performed as described above using 
10 µg of nuclear extract per condition. 
Constructs   
Full length wild type (WT) human IκBα was cloned from cDNA generated 
from normal control blood cells using the forward primer containing a BamH1 
overhang 5’-ATGGATCCGTCCGCGCCATGTTCC-3’ and the reverse primer 
containing a Sal1 overhang 5’-ATGTCGACTAACGTCAGACGCTGGCC-3’.  The 
BamH1-IκBα-Sal1 product was inserted into the expression vector pCMV-Tag4a, 
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which contains a C-terminal Flag tag.  The mutant human IκBα (IκBαW11X Mut 
1) construct was cloned from the cDNA derived from the mutant IκBα allele of the 
patient using the forward primer containing a BamH1 overhang 5’-
ATGGATCCGTCCGCGCCATGTTCC-3’ and the reverse primer containing an 
EcoRV overhang 5’-ATGATATCTAACGTCAGACGCTGGCC-3’.  The mutant 
human IκBα (IκBαW11X, Mut 2) construct was cloned from cDNA using the 
forward primer containing a BamH1 overhang 5’-
ATGGATCCCCAGGAGTAGGCCATGG-3’, which contains the coding sequence 
encompassing the second ATG within the IΚBα gene (Fig. 2.4A), and the reverse 
primer containing am EcoRV overhang 5’-
ATGATATCTAACGTCAGACGCTGGCC-3’.  The IκBα sequence was verified by 
sequencing in the Molecular Biology Core Facility at Children’s Hospital, Boston.  
The BamH1-IκBαW11X-EcoRV products of Mut 1 and Mut 2 were initially 
inserted into the expression vector pcDNA6.  IκBαW11X Mut 1 and Mut 2 were 
then cut from pcDNA6 using BamH1 and Sal1 and then inserted into pCMV-
Tag4a.  The sequence of all IκBα constructs was verified by sequencing in the 
Molecular Biology Core Facility at Children’s Hospital, Boston.  
Luciferase assays 
HEK293T cells were grown in DMEM media plus 10% FCS (Hyclone, 
Logan, UT) plus L-glutamine and penicillin and streptomycin (Invitrogen, 
Carlsbad, CA).  HEK293T cells were plated on poly-L-lysine coated plates and 
co-transfected with Fugene reagent (Roche, Indianapolis, IN) overnight with the 
indicated quantities of vector, WT IκBα, or IκBαW11X and 100 ng NFκB-
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luciferase reporter construct plus 10 ng pRL TK-Renilla reporter construct.  
Transfected HEK293T cells were stimulated with media or 20 ng/ml human TNFα 
(Invitrogen, Carlsbad, CA) for 6 hours.  Luciferase activity was measured using 
the Dual Luciferase Reporter Assay System (Promega, Madison, WI) according 
to the manufacturer’s recommendations.  Luciferase activity was normalized 
using Renilla. 
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RESULTS 
 
 Case Report.  A ten-year girl presented with a history of 15 episodes of 
pneumonia since 2 months of age and evidence of bronchiectasis by means of 
computed tomographic scanning. To date, the patient has not had any 
documented episodes of bacteremia and no mycobacterial infections.  She was 
born to unrelated parents, both of whom are healthy.  Physical exam was 
significant for slightly thin hair, pegged teeth, and coarse skin (Fig. 2.1).  
Additionally, she was noted to be heat intolerant and unable to sweat.  She was 
subsequently given a diagnosis of ectodermal dysplasia.   
 Immunological analysis was significant for a markedly elevated serum IgA 
level and a low serum IgM level.  Serum levels of IgG and IgG subclasses were 
normal except for a modestly decreased IgG2 level.  IgE level was normal (Table 
1).  The patient developed protective titers to immunization with tetanus toxoid; 
however, she had no specific antibody response to any of the polysaccharide 
antigens analysed that were contained in the pneumococcal polysaccharide 
vaccine Pneumovax (data not shown).  Analysis of lymphocytes revealed a 
lymphocytosis with normal percentages of T and B lymphocytes and natural killer 
cells (Table 1).  T cell proliferation in response to PHA-P, anti-CD3, anti-CD3 
plus anti-CD28, phorbol 12-myristate 13-acetate plus ionomycin, tetanus, and 
diptheria was normal (Fig. 2.2).  Oxidative burst was normal, as determined by 
dihydrorhodamine assay (data not shown).  
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Figure 2.1:  Photograph of patient with ED-ID 
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Figure 2.2:  Evaluation of T cell proliferation.  PBMCs (200,000/condition) from a normal 
healthy control and the patient were incubated in triplicate with media, phytohemagglutinin (PHA), 
anti-CD3, anti-CD3 plus anti-CD28, and phorbol-myristate-acetate plus ionomycin for 3 days, 
followed by incubation overnight with 3H-thymidine (0.8 mCi/well).    Also, PBMCs were incubated 
in triplicate with media (control), tetanus toxoid, or diptheria for 5 days in the Clinical Immunology 
laboratory at Children’s Hospital, Boston.  Data is representative of two experiments. 
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 Impaired cytokine production in response to TLR ligands. The 
presence of ectodermal dysplasia and recurrent infections is consistent with 
defective activation of NFκB7. In order to assess the patient’s NFκB function, we 
evaluated her ability to produce NFκB-dependent cytokines in response to TLR 
ligands21. Stimulation of the patient’s blood cells with Poly I:C (TLR3), 
lipopolysaccharide (TLR4), flagellin (TLR5), and ODN2216 (TLR9) demonstrated 
significant impairment in TNFα production, whereas 3M-13 (TLR7) stimulation 
induced normal TNFα production (Fig. 2.3A). Engagement of TLR3, TLR7, TLR8 
and TLR9 stimulates production of type I interferons, which is also dependent 
upon NFκB activation. Stimulation of the patient’s blood cells with TLR3 and 
TLR9 ligands demonstrated markedly impaired production of IFNα, whereas 
IFNα production in response to TLR7 ligand was less impaired (Fig. 2.3B).  Thus, 
the patient’s blood cells demonstrate defects in the production of the NFκB-
dependent cytokines TNFα and IFNα. 
 Heterozygous mutation in IκBα  results in the expression of an N-
terminally truncated IkBaW11X protein. To our knowledge this is the first 
known female patient with ED-ID with clinical and laboratory findings similar to 
those found in male patients with X-linked ED-ID due to mutations in IKKγ 
(NEMO). We therefore sequenced her IκBα gene, an autosomally encoded gene, 
from cDNA obtained from her blood cells. The results revealed a heterozygous 
nonsense mutation at codon 32 of IκBα (G32A; Fig. 2.4A), which was confirmed 
by sequencing exon 1 of IκBα from the patient’s genomic DNA obtained from  
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Figure 2.3:  Impaired TLR-induced NFκB-dependent cytokine production by patient 
PBMCs.   A) PBMCs (300,000/condition) were incubated with media, Poly I:C (TLR3), LPS 
(TLR4), Flagellin (TLR5), 3M-13 (TLR7), or ODN2216 (TLR9) for 12 hours, followed by collection 
of cell culture supernatants and quantitation of TNFα production by ELISA.  B) PBMCs 
(300,000/condition) were incubated with media, Poly I:C (TLR3), 3M-13 (TLR7), or ODN2216 
(TLR9) for 48 hours, followed by collection of cell culture supernatants and quantitation of IFNα 
production by ELISA  Note that TLR 9 induced IFNα production is shown on a separate graph 
due to the large quantities of IFNα induced by TLR9.  Data is representative of two experiments.
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fibroblasts. Sequencing of cDNA derived from the patient’s mother’s blood cells 
was normal (data not shown).  Unfortunately, the patient’s father is not available 
for analysis. The G32A mutation results in a W11X nonsense mutation in the 
translated protein (Fig. 2.4B). 
 Examination of the coding sequence of IκBα reveals the presence of 2 
ATG codons (Met13 and Met45 in the native IκBα) downstream from the 
nonsense mutation that are flanked by a consensus Kozak translation initiaion 
sequence22. This might allow the in-frame translation of a truncated IκBα that 
lacks the N-terminal 12 and 44 amino acids, respectively. 
Patient fibroblasts express a mutant IκBαW11X protein that fails to 
be phosphorylated and degraded after IL-1 stimulation. To determine 
whether a protein product is translated from the mutant IκBα allele, cell lysates 
were prepared from unstimulated and IL-1-stimulated primary dermal fibroblasts 
of the patient and a healthy control subject and elecrophoresed on 12% 
polyacrylamide gels to resolve proteins close in molecular weight. The gels were 
Western blotted for IκBα using 2 different antibodies, one directed against full 
length IκBα, and another directed against an N-terminal peptide of IκBα (amino 
acids 1-30).  Western blot of unstimulated normal fibroblast lysates with both 
antibodies revealed a single band that corresponded to WT IκBα.  In contrast, 
Western blotting of lysates from the patient with antibody to full-length IκBα 
revealed 2 species of IκBα, a band of normal size that corresponded to WT IκBα 
and a smaller-sized species (Fig. 2.4C).  The N- terminus antibody failed to 
recognize the smaller-sized IκBα band in the lysates from the patient’s cells,  
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Figure 2.4:  Sequencing and Western blot of IκBα from the patient.  A) IκBα was amplified 
from cDNA generated from the patient’s PBMCs.  Sequence analysis reveals a heterozygous G 
to A transition at codon 32 of IκBα.  The G32A mutation is shown in red.  The wild type start 
codon is shown by arrow 1 and a second putative start codon is shown by arrow 2.  Sequencing 
was performed two times.  B) The putative translated mutant IκBα protein is shown.  The W11X 
mutation within the signal response domain (SRD) is in red and the deleted N terminal 12 amino 
acids of IκBα is shown in red.  The position of the putative secondary translation initiation start 
site relative to lysines 21 and 22 and serines 32 and 36 is shown.  C) Anti-full length 
IκBα Western blot of fibroblast lysates from a normal control and the patient reveals a smaller 
protein product from the mutant IκBα allele (IκBαW11X) from the patient.  Western blot with anti-
N terminal IκBα antibody does not detect IκBαW11X.   D)  HEK293T cells were transfected 
overnight with 1 µg Flag-WT IκBα,  1 µg Flag- IκBαW11X (Mut 1), or 1 µg Flag-IκBαW11X (Mut 
2).  IκBα was immunoprecipitated with anti-Flag antibodies and Western blotted with anti-FL IκBα 
or with anti-N-terminal IκBα. 
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which is consistent with N-terminal truncation of the mutant. These results 
indicate that the heterozygous mutation in the patient results in the expression of 
an N-terminally truncated IκBαW11X protein. 
Activation of NFκB requires the phosphorylation of IκBα on serines 32 and 
36, followed by ubiquitination of IκBα on lysines 21 and 22 and its degradation by 
the proteasome. This allows NFκB to translocate to the nucleus and activate 
gene transcription4. Because the IκBαW11X mutant might contain serines 32 and 
36, as well as lysines 21 and 22, we evaluated whether IκBαW11X undergoes 
normal phosphorylation and degradation. Control and patient fibroblasts were 
stimulated with IL-1, and cell lysates were Western blotted with anti-phospho-
IκBα antibody and anti-IκBα against the full-length protein. Western blot with 
anti-phospho-IκBα antibody demonstrated that WT IκBα protein was 
phosphorylated within 5 minutes of stimulation in control fibroblasts. This was 
accompanied by a shift in molecular weight in blots with anti-full length IκBα 
antibodies (Fig. 2.5, lane 2).  Similarly, in the patient’s cells, the product of the 
normal allele full-length WT IκBα was also phosphorylated and underwent a 
molecular weight shift at the 5 minute time point, confirming the intact activation 
of the IKK complex in the patient’s cells. In contrast, there was no evidence of 
phosphorylation of IκBαW11X mutant, as indicated by the absence of a lower 
molecular weight band in the phospho-IκBα blot (Fig. 2.5, lane 7). Lysates were 
probed with anti-phosphop38 MAPK antibodies to demonstrate that IL-1 
activated control and patient fibroblasts equivalently. Stimulation of control and  
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Figure 2.5: Patient fibroblasts express a mutant IκBαW11X protein that does not undergo  
IL-1 induced phosphorylation and degradation. Western blotting of lysates from control and 
patient fibroblasts after stimulation with IL-1 is shown. The blot was first probed with with anti-
phopsho IκBα and then stripped and re-probed sequentiall with anti-full length (FL) IκBα, anti-N-
terminal IκBα, anti-phospho-p38MAPK, and anti-p38MAPK as a protein loading control.  The 
experiment is representative of three independent experiments. NL: healthy control; PT: patient. 
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patient fibroblasts with IL-1 resulted in equivalent activation of p38 MAPK (Fig. 
2.5). 
Western blotting of IκBα demonstrated that WT IκBα was completely 
degraded within 15 minutes in both control and patient fibroblasts.  In contrast, 
the IκBαW11X protein was not significantly degraded over the course of 1 hour, 
as evidenced by the persistence of the lower molecular weight band recognized 
by the anti-full length IκBα antibody. Degradation of WT IκBα in IL-1-stimulated 
control fibroblasts was followed by its synthesis, as indicated by its reappearance 
and phosphorylation at 1 hour (Fig. 2.5, lane 5).  In contrast, one hour after IL-1 
stimulation reappearance of WT IκBα was not evident in the patient’s fibroblasts 
(Fig. 2.5, lane 10).  Because the synthesis of IκBα is NFκB dependent, these 
results are consistent with impaired activation of NFκB. 
The IκBαW11X mutatnt retains p65 in the cytoplasm after activation 
of the patient’s cells. Because the IκBαW11X mutant does not undergo normal 
IL-1-induced phosphorylation and degradation, we examined whether it retains 
NFκB following activation with IL-1. Control and patient’s fibroblasts were 
stimulated with IL-1, then IκBα was immunoprecipitated with an anti-full length 
IκBα antibody and the IκBα immunopreciptates were probed with anti-p65 
antibodies to detect co-precipitating p65. In unstimulated fibroblasts from the 
healthy control subjects and the patient, p65 coprecipitated with IκBα. Following 
stimulation of normal fibroblasts with IL-1, p65 was no longer detected in IκBα 
precipitates, consistent with complete degradation of IκBα and release of p65.  In 
contrast, a sizeable fraction of p65 remained associated with IκBαW11X  
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following stimulation of the patient’s fibroblasts with IL-1, which is consistent with 
the persistence of the IκBαW11X mutant (Fig. 2.6A). Because of the IκBα 
degradation, signal transducer and activator of transcription1 (STAT1) Western 
blotting was performed on equal aliquots of fibroblast lysates to demonstrate 
equal protein content of the lysates used in the immunoprecipitation.  
The persistent association of p65 with the IκBαW11X mutant after IL-1 
activation suggests that a portion of p65 remains retained in the cytoplasm in the 
patient’s cells. Cytosolic fractions of control and patient fibroblasts were prepared 
following IL-1 stimulation and probed for p65 to confirm this (Fig. 2.6B). As 
expected, p65 virtually disappeared from the cytosolic fractions of control 
fibroblasts stimulated with IL-1. Twenty minutes after stimulation only 18% ± 3% 
of total cellular p65 was retained in the cytoplasm. In contrast, 55% ± 10% of 
total cellular p65 remained in the cytosolic fractions of the patient’s fibroblasts 
after IL-1 stimulation for 20 minutes (p = .004). These results suggest that 
IκBαW11X is a persistence-of-function mutant that sequesters NFκB in the 
cytoplasm after receptor stimulation. 
Impaired nuclear translocation of NFκB in patient’s cells. Because the 
IκBαW11X mutant retains NFκB, we predicted that translocation of NFκB to the 
nucleus and binding to DNA would be reduced in the patient’s fibroblasts 
following activation with IL-1.  Control and patient fibroblasts were stimulated with 
IL-1 over a 1-hour time course and nuclear extracts were examined for the 
presence of p50 and p65 (Fig. 2.7A).  Western blot of nuclear extracts with an 
antibody against the p65 subunit of NFκB demonstrated that the nuclear  
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Figure 2.6:  NFκB p65 is persistently bound by IκBαW11X in patient fibroblasts.  A) Lysates 
of fibroblasts stimulated with media or 25 ng/ml IL-1 for the indicated times were 
immunoprecipitated with non-specific rabbit IgG (ctrl IgG) or anti-IκBα and were Western blotted 
with mouse anti-p65 and anti-IκBα antibodies. 15 µl of each lysate was Western blotted with anti-
signal transducer and activator of transcripton1 (STAT1) to verify the presence of equal amounts 
of protein.  B) Western blotting of cytosolic fractions with anti-p65 and anti-STAT1.  Data is 
representative of three independent experiments. 
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translocation of NFκB was reduced in the patient’s cells. Densitometric analysis 
of the intensity of the p65 and p50 bands at the 20-minute time point in control 
and patient fibroblasts showed that nuclear accumulation of p65 and p50 in the 
patient’s cells was reduced by 40% ± 5% and 50% ± 10%, respectively, 
compared with that seen in control cells. These results are consistent with 
impaired nuclear translocation of NFκB in the patient’s cells after stimulation. 
The binding of NFκB to DNA in nuclear extracts from normal and patient’s 
fibroblasts was evaluated by electrophoretic mobility shift assay (EMSA). Figure 
2.7B shows that stimulation with IL-1 resulted in an increase in the capacity of 
nuclear extracts from control fibroblasts to bind an NFκB-specific oligonucleotide 
probe, as evidenced by an increase in the intensity of the two retarded bands 
present in unstimulated cells and by the appearance of a new retarded third 
band.  Addition of anti-65 antibody to the nuclear extracts supershifted the upper 
band in the retarded complexes. Consistent with the impaired nuclear 
translocation of NFκB in the patient’s fibroblasts, binding of nuclear extracts from 
IL-1-stimulated patient’s fibroblasts to the NFκB-specific oligonucleotide probe 
was reduced by approximately 47% ± 6% compared with that seen in control 
cells, as determined by means of densitometric analysis of the supershifted 
bands (Fig. 2.7B). 
 The IκBαW11X mutant does not exert a dominant negative effect on 
NFκB activation. HEK 293T cells were cotransfected with an NFκB-Luciferase 
expression construct and with increasing quantities of Flag-tagged WT IκBα or 
Flag-tagged IκBαW11X mutant to test whether the IκBαW11X mutant acts as a  
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Figure 2.7:  Reduced NFκB nuclear translocation and binding to 32P-labeled NFκB-specific 
oligonucleotide in nuclear extracts from patient fibroblasts.  Fibroblasts were stimulated with 
media or 25 ng/ml IL-1 for the indicated times.  A) 10 µg of each nuclear extract was resolved by 
10% SDS-PAGE and transferred to Immobilon.  Western blot with anti-NFκB p65 (p65) was 
performed to evaluate nuclear translocation.  Blot was stripped and re-probed with Anti-PARP as 
a protein loading control.  B) Nuclear extracts were generated and 2 µg of protein from each 
nuclear extract was used for NFκB EMSA.  Anti-p65 antibodies were used in one reaction to 
demonstrate specificity of the assay. Data is representative of three independent experiments. 
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dominant negative mutant, as has been reported for the IκBαS32I mutant. 
Consistent with the function of IκBα as an inhibitor of NFκB activity, transfection 
with increasing amounts of WT IκBα led to a dose-dependent inhibition of NFκB-
luciferase activity. Transfection of IκBαW11X mutant resulted in a comparable 
dose-dependent inhibition curve (Fig. 2.8A).  Western blotting of cell lysates with 
anti-Flag antibody demonstrates that WT IκBα and IκBαW11X were expressed 
comparably (Fig. 2.8B). Note that expression of IκBα in 293T cells transfected 
with 30ng of the constructs was less than the limit of detection of by means of 
Western blotting with anti-Flag. Taken together, these data indicate that 
IκBαW11X is not a dominant negative mutant but rather a persistence-of-function 
mutant that results in functional NFκB haploinsufficiency. 
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Figure 2.8: IκBαW11X does not exert a dominant negative effect.  A) HEK293T cells were 
co-transfected Flag-WT IκBα, or Flag IκBαW11X and 100 ng NFκB-luciferase reporter construct 
and TK-Renilla reporter construct and then stimulated with media or 20 ng/ml TNFα for 6 hours. 
Fold activation of luciferase activity was calculated relative to unstimulated HEK293T cells 
transfected with 500 mg vector DNA.  Transfection efficiency was normalized using Renilla. B) 
Anti-Flag Western blot of cellular lysates. 
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DISCUSSION 
 
 We describe a female patient with ED-ID associated with a novel 
heterozygous nonsense mutation in the IκBα gene that gives rise to a truncated 
protein that lacks the N-terminus of IκBα. The mutant protein is not 
phosphorylated or degraded following IL-1 receptor signaling. As a result, it 
sequesters NFκB and results in functional NFκB haploinsudfficiency.  
To our knowledge, the patient we have described is the first reported 
female with ED-ID. She has several of the classical features of ED including 
teeth abnormalities, receding hairline (Fig. 2.1) and inability to sweat23. She 
suffered from recurrent infections and exhibited immunological defects common 
to other described ED-ID patients, which included lymphocytosis, impaired 
specific antibody responses to polysaccharide antigens, and elevated IgA levels. 
Her PBMCs showed impaired response to Toll receptor ligands, characteristic of 
patients with ED-ID (Fig. 2.2)10, 18.  
A heterozygous missense mutation (G32A) in IκBα introduced a stop 
codon at position 11 in the patient (Fig. 2.3A and B). This might have allowed 
translation initiation at the second or fourth methionine codons. We indeed 
demonstrated the presence of an N-terminally truncated protein in the pateint’s 
cells. The exact start site that is used to generate this protein remains to be 
determined. The mutant IκBαW11X protein is not phosphorylated nor degraded 
following of IL-1 receptor engagement. This resulted in retention in the cytosol of 
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approximately half of p65 after stimulation and in a corresponding reduction in 
the nuclear translocation of p65 (Fig. 2.5 and 2.6).  
The immunodeficiency in our patient is less severe than that in the 2 
patients previously described with an S32I mutation in IκBα. These two patients 
had a hyper-IgM syndrome with high serum IgM and low serum IgG levels, 
absent specific antibody responses to both protein and polysaccharide antigens 
and absent antigen-stimulated T cell proliferation.  Both patients underwent bone 
marrow transplantation due to the severity of their recurrent infections10, 11. In 
contrast, our patient has normal serum IgG levels, good antibody responses to 
the protein antigen tetanus toxoid and normal T cell proliferation to antigens.  
More importantly, she has been in relatively good health while receiving 
intravenous immunoglobulin infusions, and to date has not suffered from 
mycobacterial infections that commonly occur in patients with ED-ID,  
The milder clinical phenotype of the patient compared to the two patients 
with the S32I mutation in IκBα is likely explained by the milder impairment of 
NFκB activation in this patient, although differences in the genetic background 
may have also contributed. Both the IκBαS32I and IκBαW11X mutations prevent 
ligand-induced phosphorylation and degradation of the mutant IκBα and there for 
are persisitence-of-function mutants. However, in the case of the S32I mutation, 
TNFα-induced phosphorylation and degradation of the product of the normal 
IκBα allele is barely detectable10. In contrast, IL-1 induced phosphorylation and 
degradation of the product of the normal IκBα allele is intact in our patient.  
Consistent with these observations, TNFα stimulated activation of NFκB in 
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fibroblasts from the patient with the S32I mutation was barely detectable, 
whereas IL-1 stimulated activation of NFκB in fibroblasts from our patient was 
roughly half that of the healthy control, as determined by means of scanning 
densitometry of NFκB nuclear translocation and EMSA data.  
A dominant negative effect of the S32I mutation was confirmed in 
transfection studies in which the capacity of IκBαS32I and WT IκBα to inhibit 
TNFα-driven NFκB-luciferase reporter gene expression was compared. The S32I 
mutant exerted a dominant negative effect because it was much more potent 
than WT IκBα in inhibiting reporter gene expression10. These results suggest that 
in addition to being a persistence-of-function mutant, the S32I mutant functions 
as a dominant-negative mutant. This is possibly because the S32I mutant, which 
has an intact signal response domain, might compete with WT IκBα for IKK and 
perhaps function as an irreversible inhibitor of IKK. In contrast, IκBαW11X 
exerted no detectable dominant-negative effect because its effect was 
comparable with that of WT IκBα. Because this mutant lacks a portion of the N-
terminus of IκBα, it might not effectively compete for IKK. In future experiments 
we plan to transfect IκBα-/- murine embryonic fibroblasts with WT IκBα and 
IκBαW11X to confirm that IκBαW11X functions as a persistence-of-function 
mutant. This will have the advantage of using cells without endogenous IκBα. 
In summary, the novel IκBαW11X mutant we describe in this report, which 
does not undergo normal ligand-induced degradation and which impairs NFκB 
activation through persistence of function (eg, retention of NFκB), simply results 
in functional NFκB haploinsufficiency. The fact that functional NFκB 
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haploinsufficiency was associated with ED-ID strongly suggests that normal 
ectodermal development and immune function are stringently dependent on 
NFκB, in that they might require more than half of normal NFκB activity.   
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Heterozygous S32I mutation in IκBα that causes ectodermal dysplasia with 
immunodeficiency results in defective development of lymphoid organs 
and impaired B cell function 
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I performed all experiments in this chapter. 
 96 
Heterozygous S32I mutation in IκBα that causes ectodermal dysplasia with 
immunodeficiency results in defective development of lymphoid organs 
and impaired B cell function 
 
Jana L. Mooster1, Severine Le Bras1, John Manis2 and Raif S. Geha, MD1, 
 
1Division of Immunology and 2Division of Transfusion, Children’s Hospital, 
1Department of Pediatrics and 2Department of Pathology, Harvard Medical 
School, Boston, MA, 
 
 
  
 
 97 
ABSTRACT 
Autosomal ectodermal dysplasia with immunodeficiency (ED-ID) is caused 
by mutations in the inhibitor of NFκB α (IκBα), which is phosphorylated and 
degraded in response to immune signaling pathways. We generated a mouse 
model of ED-ID by replacing one IκBα allele with a non-phosphorylatable IκBα, 
IκBα S32I, which resulted in decreased NFκB signaling. These mice have 
dysmorphic hair and teeth, as well as decreased serum immunoglobulins, and a 
severe decrease in their specific antibody response to T-dependent and T-
independent antigens. The mice lack lymph nodes (LN) and Peyer’s patches 
(PP), have a disrupted splenic architecture with no marginal zone, and fail to 
develop germinal centers (GCs).  T cell function is intact but B cell function is 
deficient in vitro. Rag2-/- bone marrow chimeras formed proper lymphoid organs 
and had normal cutaneous hapten sensitivity but did not produce specific 
antibodies. This mouse model shows that autosomal dominant ED-ID results in 
failure to develop LN and PP, disorganized splenic architecture, failure to 
develop GCs and an intrinsic B cell defect. 
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INTRODUCTION 
  
Both innate and adaptive immune responses depend on activation of 
nuclear factor κB (NFκB), a transcription factor that is induced upon ligation of 
Toll-like receptors (TLRs), TNF-family cytokine receptors and antigen receptors. 
Stimulation through these receptors causes activation of the IκB kinase (IKK) 
complex, which contains the catalytic subunits IKKα and IKKβ, and the regulatory 
subunit IKKγ, also called NFκB essential modulator (NEMO). NFκB dimers are 
retained in the cytoplasm by the inhibitors of NFκB (IκB) family, including IκBα, 
IκBβ and IκBε, which prevent the nuclear translocation of NFκB1. In the canonical 
NFκB signaling pathway, the activated IKK complex phosphorylates IκBα at Ser 
32 and Ser 36, which targets its polyubiquitination, and subsequent degradation 
by the 26S proteasome. The released NFκB dimers (primarily p50/p65) 
translocate to the nucleus and activate transcription of genes encoding 
chemokines, cytokines, adhesion molecules and inhibitors of apoptosis2, 3.  
There is a growing understanding of the family of diseases resulting from 
mutations in the NFκB signaling pathway4-6. Patients with hypomorphic mutations 
in NEMO have X-linked ectodermal dysplasia associated with immune deficiency 
(ED-ID), characterized by recurrent pyogenic infections; 
hypogammaglobulinemia with low IgG and variable serum IgM and IgA; specific 
antibody deficiency, particularly to polysaccharide antigens; and decreased 
cytokine and type I interferon production6. The ectodermal dysplasia is caused by 
defective NFκB signaling downstream of ectodysplasin A (EDA) and its receptor, 
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which regulate ectodermal development. ED is characterized by abnormal 
development of the ectoderm, including sparse hair, conical teeth and reduced 
sweat glands4, 7, 8.  
Autosomal dominant ED-ID is caused by mutations in the IκBα gene. Four 
heterozygous mutations in five patients have been described. Two patients had a 
heterozygous serine to isoleucine at position 32 in IκBα (IκBαS32I) and the other 
three had a nonsense mutation (W11X, E14X and Q9X), which resulted in the 
expression of an N-terminally truncated IκBα protein. In each case, the mutation 
impaired IKK phosphorylation and degradation of the mutant protein9-13. These 
mutations caused sequestration of NFκB in the cytoplasm by the product of the 
mutant allele, which resulted in the attenuation of NFκB activation. The two 
patients with the S32I mutation had severe recurrent pyogenic infections, low 
IgG, high IgM and low IgA levels in the serum, made no specific antibodies to 
immunization, and had an impaired T cell response to anti-CD3. They also had a 
profound deficiency in memory T cells and γδ T cells9, 10. Both patients with the 
S32I mutations and the patient with the E14X mutation received bone marrow 
transplantation. Only one of the three survived. This patient has 100% chimerism 
and normal T cell proliferation, but continues to have impaired immune function 
and requires intravenous gammaglobulin replacement and trimethoprim/ 
sulfamethoxazole prophylaxis against opportunistic infections14. The fourth 
patient with the W11X mutation also had recurrent infections but had a milder 
clinical course and is doing relatively well on gammaglobulin and 
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trimethoprim/sulfamethoxazole prophylaxis11. Treatment for the fifth patient with 
the Q9X mutation is unknown. 
The rarity of patients with ED-ID, as well as logistical considerations, 
makes it difficult to investigate their immune function in detail. We have created 
an IκBα S32I knock-in mouse model of ED-ID in order to gain insights into the 
disease. IκBα S32I knock-in mutant mouse recapitulates many of the ectodermal 
and immune abnormalities found in patients with ED-ID due to IκBα mutation, 
including poor responses to TLR and poor antibody responses due to an intrinsic 
defect in B cell function. In contrast, these mice had no intrinsic T cell defect. 
However, they lack lymph nodes (LN) and Peyer’s patches (PP), follicular 
dendritic cells (FDCs) and germinal centers (GCs). These abnormalities were not 
due to intrinsic defects in hematopoietic cells, and may have resulted from 
defective NFκB signaling in stromal cells. 
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MATERIALS AND METHODS 
 
Generation of Heterozygous IκBα  S32I Knock-in Mice 
The arms of the IκBα S32I targeting vector were amplified by PCR from 
genomic DNA of the CJ7 ES cell line derived from the 129Sv mouse strain. The 
2.8-kb 5′ and 3.1-kb 3′ arms were cloned into the pKS-neo-DTAIII vector (a gift 
from the lab of Dr. Michael Greenberg) and the nucleic acid G94T mutation was 
introduced by site-directed mutagenesis (Stratagene) into exon 1 in the 5′ arm 
resulting in the amino acid S32I mutation (Fig. 3.1A). The linearized targeting 
construct was electroporated into CJ7 ES cells, which were then selected in 0.4 
mg/ml G418 and 10 mg/ml gancyclovir. An ES cell clone containing a disrupted 
allele and no random integration of the neo gene was confirmed by PCR and 
Southern blotting (Fig. 3.1B), then injected into 3.5-day-old C57BL/6 blastocysts, 
and IκBα S32I heterozygous neo mice were obtained by standard methods15. 
Presence of mutant RNA was confirmed by amplifying cDNA with the primers 
CAGGACTGGGCCATGGAG and ATCTCCCGCAGCTCCTTC, followed by a 
digest with MwoI. 
Mice were back-crossed six generations to C57Bl6 mice from Charles 
River Labs. All mice were kept in a specific pathogen-free environment, in 
autoclaved cages with trimethoprim and sulfamethoxazole added to the water. 
Procedures were performed in accordance with the Animal Care and Use 
Committee of the Children’s Hospital Boston. 
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Western Blotting 
Primary dermal fibroblast cultures were grown in RPMI media plus 10% 
FCS (Hyclone, Logan, UT) plus L-glutamine, penicillin and streptomycin 
(Invitrogen). Fibroblasts were stimulated with media, 10ng/ml IL-1, 10ng/ml 
TNFα (R&D systems), or 1mg/ml LPS (Sigma) for the indicated times. Western 
blotting was performed as previously described11 using anti-phospho IκBα (Cell 
Signaling), anti-mouse full-length IκBα (Abcam) and anti-actin (Sigma), according 
to the manufacturer’s recommendations. 
Sheep anti-mouse horseradish peroxidase–conjugated and sheep anti-
rabbit horseradish peroxidase–conjugated secondary antibodies were obtained 
from GE Healthcare (Piscataway, NJ). Quantification was performed using the 
public domain ImageJ software from the National Institutes of Health. 
 
FACS Analysis 
Single-cell suspensions from 4 to 6 wk old mice were stained with FITC, 
PE, PE-Cy7, APC, PerCP-Cy5.5, AlexaFluor 700, or APC-eFluor 780-labeled 
monoclonal antibodies and analyzed on a FACS Canto (BD). Antibodies to B220, 
CD3, IgM, CD21, CD23, CD93, CD43, CD4, CD8, GL-7, Mac-1, CD11b, and 
Ly6G were from eBioscience, Fas was from BD Pharmingen and FITC-
conjugated PNA was from Sigma.  
Murine embryonic fibroblasts were treated for 24 hours with 2µg/ml anti-
LTβR agonist antibody AFH6 (a gift from Jeff Browning, Biogen) or 10ng/ml 
TNFα, dissociated with trypsin/EDTA, and stained with anti-VCAM1 
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(eBioscience). 
 
Immunohistochemistry 
IHC was performed as described in Cariappa, et al16 and Kranich, et al17. 
 
Purification and Stimulation of Splenic T and B cells 
Assays for proliferation, cytokine production, and GC formation were 
performed as previously described18. Briefly, B cells were purified from spleen 
suspensions using anti-CD43 microbeads (Miltenyi) resuspended in RPMI 
supplemented with penicillin/streptomycin, HEPES (GIbco), sodium pyruvate and 
β-mercaptoethanol (Sigma). 200,000 cells in 96-well plates were plated for 
proliferation assays, and 250,000 per 24-well for in vitro Ig analysis. Cells were 
stimulated with 10µg/ml anti-µ (Jackson ImmunoResearch), 500ng/ml anti-CD40 
(eBioscience), 10µg/ml LPS (Sigma), and 40ng/ml IL-4 (R&D Systems) alone or 
in combination. Tritiated thymidine (PerkinElmer) was added at day 3, and 
incorporation was assayed after 15 to 18 hours. Supernatants from in vitro Ig 
experiments were analyzed by ELISA on day 6. 
T cells were purified from spleen suspensions using the pan-T cell 
isolation kit from Miltenyi, and 100,000 per 96-well were plated, along with 
300,000 irradiated (3000 rad) non-T cell (CD90.2 kit from Miltenyi) APCs. For 
anti-CD3 experiments, plates were coated with 0.25µg/ml anti-CD3 (eBioscience, 
clone 145-2C11) at 37C for 1 hour and washed with PBS. Cells were also 
stimulated with 200µg/ml Ovalbumin (OVA) (Sigma). Tritiated thymidine was 
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added on day 3 and incorporation was assayed after 15 to 18 hours. IL-2 
production was assayed from day 2 supernatants by ELISA (BD Bioscience). 
 
Serum Ig Levels and Antibody Responses  
4 to 6 week old mice were immunized i.p. with 50µg of OVA with Alum 
(Sigma) in PBS at day 0, boosted at day 14, and bled at days 0 and 21. Mice 
were immunized i.p. with 25 µg TNP-LPS (Biosearch Technologies) in PBS or 
with 25 µg TNP–Ficoll (Biosearch Technologies) at day 0 and bled at days 0 and 
14. Antigen-specific antibody responses were analyzed by OVA-specific or TNP-
specific ELISA using 96-well plates coated with either OVA or TNP-conjugated 
BSA (Biosearch Technologies) at 10µg/mL in PBS. For serum immunoglobulin 
levels, plates were coated with isotype-specific antibodies (Southern Biotech). 
AP-conjugated secondary antibodies(Southern Biotech) and PNPP (Sigma) were 
used for ELISA.  
 
Contact Hypersensitivity to Oxazolone 
Mice were sensitized by the application of 100 µL of 2% oxazolone 
(Sigma) in ethanol on day 1 to shaved abdominal skin. On day 5, the left ear was 
challenged with 10 µL of 1% oxazolone and the right ear was challenged with 
vehicle (ethanol) on dorsal and ventral surfaces. Ear thickness was measured 
after 24 hours with a micrometer (Mitutoyo). 
 
Bone Marrow Reconstitution of Rag2-/- Mice 
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Bone marrow was collected from 6 week old mutant mice or their WT 
littermates. Flow cytometry was performed to assure the CD34- population was 
comparable between the WT and mutant bone marrow. Adult Rag2-/-  recipient 
mice received a single 250 cGy dose of total body γ irradiation (137Cesium 
source). Viability of the bone marrow cells was examined by trypan blue dye 
exclusion and 1 × 105 viable bone marrow cells were injected i.v. into the Rag2-/- 
mice.  
 
Statistical Analysis 
Statistical Analysis of data was performed with Prism software using the 
Student’s t test or ANOVA. 
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RESULTS 
 
 
 Heterozygous IκBα S32I mutant mice have ectodermal dysplasia, 
failure to thrive and increased postnatal mortality. We generated mice with a 
G94T misense mutation in exon 1 of IκBα, which results in the substitution of 
serine at a.a. position 32 by isoleucine (S32I). The strategy for the generation of 
these mice is shown in Figure 3.1. Heterozygous pups were born at Mendelian 
ratios, indicating no embryonic lethality.  
Heterozygous IκBα S32I mutant mice, hereafter referred to as IκBα mutant 
mice, were found to have missing third molars and a lack of guard hair types 
(Fig. 3.2A). This phenotype is similar to that of mice with ectodermal dysplasia 
caused by disruption of the EDA gene8. IκBα mutant mice were significantly 
smaller in size and in weight than their WT littermates (Fig. 3.2B,C). IκBα mutant 
mice survived poorly with a 50% survival at 8 weeks (Fig. 3.2D).     
Impaired IκBα phosphorylation and degradation in IκBα mutant mice. 
It is difficult to distinguish between the WT and mutant proteins by Western blot, 
since the proteins are of the same size and there are no antibodies available that 
differentially bind to one or the other. We tested indirectly for the presence of the 
mutant protein by examining the resistance of IκBα to phosphorylation and 
degradation. Skin fibroblasts were stimulated with IL-1, a known activator of the 
canonical NFκB pathway, and cell lysates were Western blotted with anti-
phospho-IκBα (S32/S36) and anti-IκBα antibodies. WT fibroblasts exhibited 
robust IκBα phosphorylation 5 minutes after IL-1 stimulation phosphorylation (Fig.  
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Figure 3.1. Generation of IκBα  S32I mutant mice 
A. IκBα S32I targeting vector scheme. The arms of the IκBα S32I targeting vector were amplified 
by PCR from genomic DNA of the CJ7 ES cell line derived from the 129Sv mouse strain. The 2.8-
kb 5’ and 3.1-kb 3’ arms were cloned into the pKS-neo-DTAIII vector and the nucleic acid G94T 
mutation (red asterisk) was introduced into exon 1 in the 5’ arm resulting in the amino acid S32I 
mutation. B. Southern blot confirmed PCR genotyping (not shown). The neo cassette is 
approximately 1.7kb. Using the restriction enzyme NdeI, the WT allele DNA gives a band at 
5.5kb, and the targeted allele 7.2kb. The neo cassette contains a HindIII site, so the targeted 
band is smaller, 3.7kb, and the WT allele is 6.9 kb. ES cell DNA and clone 1 (negative by PCR) 
were used as negative controls. After confirmation by sequencing, clone 4 was chosen for 
blastocyst injection. 
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Figure 3.2.  Mutant mice have ectodermal dysplasia and failure to thrive 
A. The third molars (red arrows) are missing in mutant mice (left panel), and guard/tylotrich hairs 
are missing in the mutant (right panel). B. Photo and C. growth chart showing mutant mice are 
significantly smaller than their littermates. D. Survival is decreased in mutant mice. 
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3.3A). IκBα phosphorylation was distinctly weaker in fibroblasts from mutant 
mice. Densitometry scanning showed that the ratio of pIκBα:IκBα bands, as 
determined at 5 minutes, was 3.6±0.7-fold lower in the mutant fibroblasts than in 
the WT fibroblasts (Fig. 3.3B). Following IL-1 stimulation IκBα was mostly 
degraded by 15 minutes and completely degraded by 30 minutes in WT 
fibroblasts. In contrast, the ratio of the IκBα:actin bands showed markedly less 
degradation (27.8±5.5% of 0 minute timepoint) of IκBα in IL-1 mutant fibroblasts 
at all time points examined (Fig. 3.3C). Similar results to those obtained with IL-1 
stimulation were found when the cells were stimulated with TNFα and LPS, two 
other well-known activators of the canonical NFκB pathway (data not shown). 
These results demonstrate that the mutant IκBα protein is expressed in cells from 
IκBα mutant mice and is resistant to phosphorylation and degradation. 
IκBα  mutant mice lack lymph nodes.  Gross examination revealed a 
lack of detectable lymph nodes (LN) in IκBα mutant mice, including mesenteric, 
popliteal, paraaortic, inguinal, axial, and cervical LN, all of which were easily 
detected in WT littermates (Fig. 3.4A-C). Following the injection of Evan’s blue 
dye in the footpad, lymphatic vessels were readily apparent and were 
comparable in mutant and WT mice. In contrast, no LN could be detected in the 
popliteal, inguinal or para-aortic area in the mutant, but were present in the WT 
control  (Fig. 3.4B, C, and data not shown). No LN tissue could be detected in 
H&E stained serial sections of the inguinal fat pad in IκBα mutant mice (data not 
shown).  Peyer’s patches (PP) were readily visible in H&E stained sections of the 
small intestine of WT mice, but none could be detected in the mutants (Fig.  
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Figure 3.3. Mutant IκBα protein results in decreased NFκB activation 
A. Western blot showing phosphorylation and degradation of IκBα following stimulation with 
10ng/ml IL-1. B. Graph of phosphorylated IκBα/IκBα ratio, normalized to WT. C. Graph of 
IκBα/actin ratio comparing 0 and 30 min. 
 111 
 
Figure 3.4. IκBα mutant mice lack lymph nodes. 
A. Mesenteric lymph nodes (white ovals) are missing in mutant mice. B. Evan’s blue dye was 
injected into the foot pad of freshly sacrificed mice in order to view the lymphatic vessels (white 
arrows) and inguinal lymph nodes (white circle). C. Evan’s blue dye was injected into the foot pad 
of freshly sacrificed mice in order to view the para-aortic lymph nodes (white oval). D. H&E 
staining of mouse intestine showing Peyer’s patches (white arrows). E. MEF from WT or mutant 
mice were stimulated with 2µg/ml AFH6 or 10ng/ml TNFα for 24 hours and VCAM1 surface 
expression was analyzed by flow cytometry. 
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3.4D). LN organogenesis requires the lymphotoxin β receptor (LTβR) signaling in 
stromal cells mediated by contact with lymphoid tissue inducer (LTi) cells that 
express the LTβR ligand LTα1β2 on their surface19, 20 (Fig. 3.5). LTβR, as well as 
TNFR, signaling in endothelial cells causes the expression of the adhesion 
molecule VCAM1 by activation of the canonical NFκB pathway21. As previously 
reported, stimulation with the agonistic LTβR mAb AFH6 or TNFα upregulated 
VCAM1 expression by WT mouse embryonic fibroblasts (MEFs)21 (Fig. 3.4E). In 
contrast, AFH6 failed to upregulate VCAM1 expression in MEFs from IκBα 
mutant mice and TNFα weakly upregulated it. This suggests that defective LTβR 
signaling may account, at least in part, for the lack of LN and PPs in IκBα mutant 
mice.   
Disrupted architecture of lymphoid organs and absent marginal zone 
(MZ) B cells in IκBα  mutant mice. The size and cellularity of the thymus was 
comparable in WT and IκBα mutant mice (Fig. 3.6A). The distribution of 
thymocyte subsets into CD4-CD8- double negative (DN) cells, CD4+CD8+ double 
positive (DP) cells and CD4+ or CD8+ single positive (SP) cells were comparable 
in IκBα mutant mice and WT littermates (Fig. 3.6B). However, thymic architecture 
was disrupted in the IκBα mutant mice. They had a smaller medulla with a 
greater density of lymphocytes, and a lesser density of lymphocytes in the cortex 
than in WT littermates (Fig. 3.6C).  
Bone marrow cellularity and distribution of (B220+IgM-CD43+) pro-B, 
(B220+IgM-CD43-) pre-B, (B220+IgM+) immature and (B220++IgM+) mature B cell 
subsets were comparable in IκBα mutant mice and WT littermates (Fig. 3.6D).   
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Figure 3.5. Schematic of LN formation from van de Pavert and Mebius, 201019. 
Clustering of pre-LTi cells facilitates signaling through tumor necrosis factor related activation-
induced cytokine receptor (TRANCER) which leads to the induction of LTα1β2, and differentiation 
into mature LTi cells. Interaction of LTα1β2-expressing LTi cells with LTβR-expressing stromal 
cells results in their differentiation into stromal organizer cells, which express chemokines, 
adhesion molecules and cytokines. These factors support attraction and retention of more 
hematopoietic cells, leading to LN growth. 
 114 
 
Figure 3.6. Size and cellularity of thymus and bone marrow are normal in IκBα  mutant 
mice 
A. Photo of thymus from WT and mutant mice. B. Flow cytometric analysis of thymocytes 
showing CD4 and CD8 double negative, double positive and single positive populations. C. H&E 
staining of thymus from WT and mutant mice. D. Flow cytometric analysis of B220+ B cells from 
bone marrow of WT and mutant mice showing IgM+B220high mature cells, IgM+B220+ immature B 
cells, IgM- B220+ CD43- preB cells and IgM-B220+CD43+ proB cells.
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Figure 3.7. Splenic architecture in IκBα  mutant mice is impaired. 
A. Photo of spleen showing splenomegaly in the mutant. B. Flow cytometric analysis of B220+ 
and CD3+ cells in the spleen.  C. Flow cytometric analysis of CD4+ and CD8+ cells in the spleen. 
D. Flow cytometric analysis of CD11b+Ly6G+ neutrophils and E. Mac-1+ macrophages. F. Flow 
cytometric analysis of B220+ splenocytes stained with anti-CD93 to identify transitional B cells, or 
anti-CD21 and anti-CD23 to identify follicular (FO) and marginal zone (MZ) B cells. G. H&E 
staining of spleen sections. H. Immunofluorescent staining of spleen sections stained with anti-
MOMA (blue), anti-IgM (red) and anti-IgD (green) in order to show marginal zone structure. I. 
Immunofluorescent staining of spleen stroma for FDCs, red: FDCM1, blue: B220, green: SIGNR1 
to identify B cell follicles and FDCs, respectively.
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The size and cellularity of the spleen were greater in IκBα mutant mice than WT 
littermates (Fig. 3.7A). The ratio of B220+ to CD3+ cells was similar between the 
two groups (Fig. 3.7B), although there was a larger non-lymphocyte population in 
the IκBα mutant spleens. The distribution of CD4+ and CD8+ subsets were 
comparable in the two groups (Fig. 3.7C). There was an increased percentage of 
CD11b+ cells including Ly6G+ neutrophils and of Mac-1+ macrophages (Fig. 
3.7D, E). Analysis of B cell subsets showed a virtual loss of MZ B cells in IκBα 
mutant mice (0.30±0.03% of B220+ cells in IκBα mutant mice versus 5.23±0.18% 
in WT littermates, p<.001), but the percentages of transitional B cells and 
follicular B cells were normal in these mice (Fig. 3.7F).  Histological examination 
revealed poor demarcation of the white and red pulps and poorly developed 
follicles in spleens of IκBα mutant mice (Fig. 3.7G). Immunofluorescence 
analyses revealed that although MOMA+ macrophages were present in IκBα 
mutant mice, they failed to form the ring structure typical of a MZ (Fig. 3.7H). 
Immunofluorescence analysis also showed that FDCM1+ or CD35+ follicular 
dendritic cells (FDCs) were absent from the spleens of IκBα mutant mice (Fig. 
3.7I). Thus, even though T and B cell subsets, except for MZ B cells, were 
present at comparable numbers, the architecture of the spleen was severely 
disorganized. 
  Normal T cell response in vitro, but impaired delayed contact 
hypersensitivity (CHS) in IκBα  mutant mice. Purified splenic T cells from IκBα 
mutant mice and WT littermates, proliferated and secreted IL-2 to a comparable 
extent in response to immobilized anti-CD3 mAb (Fig. 3.8A). Furthermore purified  
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Figure 3.8. Response to TCR stimulation is intact, but in vivo responses involving T cells 
are impaired. 
A. Proliferation and IL-2 production from purified splenic T cells stimulated with coated anti-CD3 
mAb. WT or mutant cells stimulated with medium alone were <300 CPM, with negligible IL-2 
production. B. Proliferation and IL-2 production to OVA from splenic T cells purified from OVA-
immunized mice. C. Difference in thickness between oxazolone- and vehicle-challenged ears at 24 
hours post-challenge. D. H&E staining of oxazolone- and vehicle-challenged ears at 24 hours. E. 
H&E staining of LN from Rag2-/- mice reconstituted with WT or mutant BM. F. Cellularity of one 
axillary and one inguinal LN from each chimeric mouse. B cells were defined as B220+ and T cells 
as CD3+. G. Difference in thickness between oxazolone- and vehicle-challenged ears from 
chimeric mice at 24 hours post-challenge. H. H&E staining of oxazolone- and vehicle-challenged 
ears from chimeric mice at 24 hours. 
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splenic T cells from IκBα mutant mice and WT littermates immunized 
intraperitoneally (i.p.) with ovalbumin (OVA) were comparable in their ability to 
proliferate and secrete IL-2 in response to OVA presented by WT irradiated 
splenic non-T cells (Fig. 3.8B).  
The T cell response to cutaneously introduced antigen depends on the 
interaction in skin draining LN between recirculating antigen-specific T cells and 
DCs that have captured antigen. We investigated the ability of IκBα mutant mice 
to mount a CHS response to the hapten oxazolone. IκBα mutant mice sensitized 
with oxazolone developed significantly less ear swelling, markedly less cellular 
infiltration and edema than WT controls (Fig. 3.8C, D). These data indicate that T 
cells from IκBα mutant mice have no intrinsic defect in responding to antigen 
receptor ligation, and can be educated in vivo to respond to antigen delivered 
intraperitoneally. However they fail to be educated to cutaneously introduced 
antigen, likely because they lack LN. 
To demonstrate that the lack of LN rather than an intrinsic T cell defect is 
responsible for the inability of IκBα mutant mice to mount a CHS response, we 
reconstituted irradiated Rag2-/- mice with bone marrow (BM) from these mice and 
WT littermates. Rag2-/- mice possess LTi cells and the crosstalk between LTi cells 
and stromal cell is intact in these mice20. Thus they develop LN populated with T 
and B cells following transplantation of WT normal BM cells. LN from Rag2-/- mice 
reconstituted with BM from IκBα mutant mice (hereafter referred to as IκBα 
mutant chimeras) were comparable in size and content to LN from Rag2-/- mice 
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reconstituted with BM from WT littermates (hereafter referred to as WT chimeras) 
(Fig. 3.8E, F).  
IκBα mutant chimeras mounted a CHS response to oxazolone comparable 
to that of WT chimeras, as evidenced by ear swelling, cellular infiltration and 
edema (Fig. 3.8G, H). These findings indicate that the lack of CHS in IκBα mutant 
is not due to an intrinsic defect in hematopoietically derived cells and that the 
reduced CHS in these mice is likely due to their lack of LN. 
Impaired in vitro and in vivo B cell function in IκBα mutant mice. 
Purified splenic B cells from IκBα mutant mice proliferated significantly less in 
response to stimulation with anti-CD40+IL-4 or LPS+IL-4, compared to B cells 
purified from WT littermates (Fig. 3.9A). CFSE dilution studies showed both 
delayed and reduced proliferation in the IκBα mutant B cells (Fig. 3.9B). Purified 
IκBα mutant B cells produced significantly less IgM than WT B cells after 
stimulation with anti-CD40+IL-4 and LPS+ 
IL-4, while IgG production was not statistically different between the two groups 
(Fig. 3.9C). Serum IgM levels were comparable in IκBα mutant mice and WT 
littermates but serum IgG levels were significantly decreased in the mutants (Fig. 
3.9D). Serum IgA level was nearly absent in IκBα mutant mice. 
Antibody responses to the type I T-independent (TI) antigen TNP-LPS, the 
type II TI antigen TNP-Ficoll, and the T-dependent (TD) antigen OVA were 
severely diminished in IκBα mutant mice (Fig. 3.10A-C). The specific antibody 
response to TD antigens requires germinal center (GC) formation22. OVA 
immunization resulted in the robust development of GCs in the spleens of WT  
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Figure 3.9. B cell function is reduced in vitro and IκBα mutant mice have low serum IgM 
and IgA 
A. In vitro proliferation of purified splenic B cells to several antigens. B. CFSE dilution experiment 
showing proliferation of purified splenic B cells. C. In vitro immunoglobulin production to anti-
CD40+IL-4 and LPS+IL-4. D. Baseline serum antibody concentrations as determined by ELISA. 
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Figure 3.10. Specific antigen formation and GC formation in vivo are severely impaired 
A. TNP-specific serum Igs after immunization with TNP-LPS, reported as the difference in 
absorbance between day 14 and day 0 for each mouse. B. TNP-specific serum Ig after 
immunization with TNP-Ficoll, reported as the difference in absorbance between day 14 and day 0 
for each mouse. C. OVA-specific serum Igs after immunization with OVA, reported as the 
difference in absorbance between day 21 and day 0 for each mouse. D. B220 and PNA IHC of 
spleen sections from WT and mutant mice after 10-day immunization with OVA. E. Representative 
flow cytometric analysis after 10-day immunization with OVA (gated on B220+). GC B cells were 
identified at B220+PNA+or B220+GL7+Fas+. Unimmunized mice (un) were included as controls. F. 
Quantification of flow cytometric analysis on GC B cells. 
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Figure 3.11. Rag2-/- mice reconstituted with IκBα mutant bone marrow can form PNA+ 
germinal centers, but do not produce specific antibodies  
A. TNP-specific serum Igs after immunization with TNP-Ficoll, reported as the difference 
in absorbance between day 14 and day 0 for each chimera. B. OVA-specific serum Igs after 
immunization with OVA, reported as the difference in absorbance between day 21 and day 0 for 
each chimera. C.Representative plot and D. quantification of flow cytometric analysis of spleens 
after 10-day immunization with OVA (gated on B220+). E. Spleen sections from Rag2-/- bone 
marrow chimeras after 10-day immunization with OVA. Paraffin sections were stained with H&E, 
B220 or PNA. F. Immunofluorescent staining of spleen stroma for FDCs, red: FDCM1, blue: B220. 
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mice as evidenced by staining for peanut agglutinin (PNA). In contrast, GC 
development was severely deficient in IκBα mutant mice (Fig. 3.10D). The 
percentage of B220+PNA+ and B220+Fas+GL7+ GC B cells in the spleen was 
significantly lower in OVA immunized IκBα mutant mice than WT controls (Fig. 
3.10E,F). IκBα mutant B cells have a modest proliferation defect and the mutant 
mice are unable to form germinal centers and mount a specific antibody response 
to antigens. 
The defect in antibody production in IκBα  mutant mice is intrinsic to B cells.  
To determine if the defective antibody production in IκBα mutant mice was 
intrinsic to the B cells, we examined Rag2-/- chimeric mice. Antibody responses to 
the TI antigen TNP-Ficoll and to the TD antigen OVA were significantly lower in 
IκBα mutant chimeras than in control WT chimeras (Fig. 3.11A, B). Examination 
of spleens from IκBα mutant chimeras revealed the presence of follicles that were 
comparable in size and number to those in WT chimeras (Fig. 3.11E, left panel). 
Following i.p. immunization with OVA, the percentage of B220+PNA+ and 
B220+Fas+GL7+ cells in the spleens of immunized mice was comparable in IκBα 
mutant chimeras and WT chimeras (Fig. 3.11C, D), but antibody response 
remained deficient, indicating that an intrinstic defect exists in the B cells of IκBα 
mutant chimeras. IκBα mutant chimeras developed PNA+ GCs in their spleens 
which were similar to control WT chimeras (Fig. 3.11E, middle and right panels). 
CD35+ follicular dendritic cells are absent in Rag2-/- mice23, but were readily and 
comparably detectable in spleens of IκBα mutant and WT OVA-immunized 
chimeras (Fig. 3.11F). Therefore, in chimeric mice, where the stroma is WT, 
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spleen follicle, follicular dendritic cells and germinal center formation are 
supported. 
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DISCUSSION 
We have generated knock-in mice heterozygous for the S32I mutation in 
IκBα that abolishes ligand-induced IκBα phosphorylation and causes ED-ID in 
patients. In addition to ED, the mice lacked LN, PP, splenic follicles and FDCs, 
had severely impaired delayed contact hypersensitivity and antibody responses 
and failed to form germinal centers. All these defects, except for the defective 
antibody responses, were corrected in IκBα mutant chimeras, and thus they 
likely resulted from a defect in stromal cells.  
The IκBα S32I mutant mice had ectodermal dysplasia, similar to ED-ID 
patients carrying the same mutation and tabby mice, which have a mutation in 
the EDA gene8. The size and weight of the mutant mice were smaller than those 
of their WT littermates, possibly due to poor ability to compete against WT 
littermates for food and/or to their ectodermal defects. One ED-ID patient with the 
S32I mutation in IκBα had a reduced response to growth hormone (GH)24. The 
response to GH remains to be investigated in the mutant mice. 
The total amount of IκBα protein appeared to be comparable in mutant 
and WT fibroblasts. Since IκBα is under transcriptional regulation by NFκB, 
diminished NFκB activation in the mutant would result in lower expression of both 
alleles.  However, this would be counterbalanced by decreased degradation of 
mutant protein, leading to a relative increase of IκBα mutant protein compared to 
WT protein. This would explain the comparable amounts of total IκBα protein in 
mutant and WT fibroblasts. We were unable to evaluate the relative expression 
levels of the mutant and WT proteins in the mutant fibroblasts, because the two 
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proteins migrate together and there are no available antibodies that distinguish 
between them. Nevertheless, a portion of the protein does not degrade after 
stimulation, and the disease is recapitulated in these mice. 
Following IL-1 stimulation, virtually 100% of the IκBα protein was 
degraded in WT fibroblasts. In contrast, IL-1 stimulation resulted in the 
degradation of only ~20% of IκBα protein in the mutant fibroblasts. Assuming a 
comparable translation efficiency of WT and mutant mRNA, this result strongly 
suggests that the mutant protein accumulates to a higher level than the WT 
protein. In addition, the mutant might interfere with the degradation of WT protein 
by sequestering the IKK complex, and undegraded WT protein would account for 
some of the IκBα protein that remains intact following IL-1 stimulation of the 
mutant. One or both of these mechanisms would explain the previous 
observation that the S32I mutant acts as a dominant negative in an NFκB 
reporter gene assay9.  
IκBα mutant mice completely lacked LN and PP. The formation of LN and 
PP depends on the interaction of stromal cells with CD4+CD3-IL-7Rα+ LTi cells, 
which express TNFα and LTαβ. This results in the activation of the NFκB 
pathway in stromal cells, which is essential for LN formation. This is evidenced 
by the observation that LTβR-/- LTα-/- and RelA-/-/TNFR-/- mice have absent LN 
and PP, while TNFα-/-  and TNFR-/-  mice  have poorly formed PP. LTi cells do not 
depend on NFκB for their development, as they are present in normal numbers in 
RelA-/-/TNFR-/- mice25. We therefore do not expect their numbers to be reduced in 
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the IκBα mutant mice. Direct proof of normal LTi numbers in the mutant mice will 
require direct examination of CD4+CD3-IL-7Rα+ LTi cells in embryonic intestines.  
TNFα and LTβR signaling in stromal cells results in the expression of 
adhesion molecules, including VCAM1, which are essential for LN and PP 
formation19. We gathered strong evidence that TNFα signaling and signaling via 
LTβR are deficient in the mutant. Using MEFs, we showed that TNFα and ligation 
of LTβR by agonistic mAb failed to upregulate the expression of the adhesion 
molecule VCAM1 in the mutant. This result strongly suggested that impaired 
NFκB signaling in stromal cells underlies the failure of IκBα mutant mice to form 
LN and PP. This was supported by the observation that BM cells from the mutant 
reconstituted LN and PP in Rag2-/- recipients. The observation that IκBα mutant 
lymphocytes populated LN, PP (data not shown) and spleen in Rag2-/- recipients 
also rules out a homing defect in lymphocytes from IκBα mutant mice.  
IκBα mutant mice lacked MZ and B220+CD21+CD23- MZ B cells in their 
spleens.  MOMA+ macrophages which are normally adjacent to MZ B cells and 
form a ring-like structure outside the follicle, were present in apparently normal 
numbers, but were dispersed. Proper MZ formation, like LN and PP formation, 
depends on TNFα and LTβR activation of the NFκB pathway in stromal cells. 
This is evidenced by the observation that LTβR-/-, LTα-/- and p50-/- mice have no 
MZ B cells, and TNF-/- and TNFR-/- mice have reduced MZ26. TNFα and LTβR 
signaling in stromal cells results in NFκB mediated upregulation of the 
expression of the adhesion molecule MAdCAM1, which is critical for MZ 
formation27. MAdCAM1 expression was absent in spleens from mutant mice 
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(data not shown), implicating failure to express MAdCAM1 in the lack of MZ 
development in these mice. MZ formation has been reported to be dependent on 
BCR dependent NFκB activation in B cells28. MZ B cells were reconstituted in 
IκBα mutant Rag2-/- chimeras indicating that a B cell intrinsic defect did not 
contribute to the lack of MZ in the mutant. This is consistent with findings in RelA-
/-/TNFR-/-->Rag2-/- chimeras25. 
IκBα mutant mice lacked FDCs and B cell follicles, and failed to form GCs. 
Spleens from IκBα mutant mice lacked FDCM1+ cells and had poorly formed 
follicles. Following i.p. immunization with OVA, IκBα mutant mice failed to 
develop GCs,  as evidenced by lack of PNA+ staining of spleen sections and lack 
of B220+PNA+ and B220+Fas+GL7+ cells by FACS analysis. FDCs are derived 
from non-hematopoietic stromal cell precursors and play an important role in the 
formation of follicles and GCs. NFκB activation by TNFR and LTβR signaling in 
stromal cells and TNFα and LTα1β2 expression on B lymphocytes are important 
for FDC development and the formation of B cell follicles and GCs.  This is 
evidenced by the observation that LTβR-/-, LTα-/-, LTβ-/- TNFα-/- and TNFR-/- mice, 
and mice whose B cells lack TNFα and LTβ have no FDCs and do not form 
follicles or GCs26, 29. FDCs, follicles and GC formation were all restored in IκBα 
mutant Rag2-/- chimeras. This observation, together with the finding that T cells 
from IκBα mutant mice proliferated normally to OVA and expressed normal 
amounts of CD40 ligand following anti-CD3 stimulation, rules out a role for a T 
cell defect in the failure of GC formation in these mice. Taken together, these 
results strongly suggest that impaired NFκB signaling in stromal cells resulted in 
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the failure of FDC development, and the subsequent failure to form follicles and 
GCs in IκBα mutant mice.  
Except for the lack of MZ B cells, T and B cell numbers and subset 
distribution in the spleen were comparable in numbers and percentages in the 
spleen of IκBα mutant mice. This is consistent with a normal T and B cell 
distribution in the peripheral blood of ED-ID patients with the same IκBα 
mutation9, 10. GCs are not formed, so post-GC subsets were not enumerated in 
these mice. There was no discernable intrinsic defect in T cells from IκBα mutant 
mice. Splenic T cells from these mice proliferated and secreted IL-2 normally in 
response to anti-CD3 and antigen administered i.p. In contrast, CHS 
hypersensitivity was severely impaired in IκBα mutant mice. Successful 
sensitization to skin painting with hapten requires the encounter between hapten-
laden DCs and recirculating antigen specific T cells in skin draining LN 30. This is 
evidenced by the observation that CHS is severely deficient in LTα-/- mice, which 
lack LN 31. CHS was restored in IκBα mutant chimeras, indicating that the 
defective CHS in IκBα mutant mice was not due to an intrinsic T cell defect, but 
to their lack of LN. In contrast to T cells from our mutant mice, T cells from ED-ID 
patients with the same IκBα S32I mutation have impaired proliferation to anti-
CD3, which, however, was restored by anti-CD28 or IL-29, 10. The reason for this 
difference is not clear but may relate to the persistent presence of infections in 
the patients, and the absence of obvious infections in the IκBα mice which were 
kept in autoclaved cages in a specific pathogen free facility and on oral 
sulfamethoxazole and trimethoprim prophylaxis. 
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B cells from IκBα mutant mice had a modest, but significant reduction in 
their ability to proliferate in response to all stimuli tested. These included BCR 
ligation with anti-IgM (BCR crosslinking), anti-CD40+IL-4 (CD40 ligation) and 
LPS+IL-4 (TLR ligation). B cells from IκBα mutant mice also secreted less IgM 
and IgG in response to anti-CD40+IL-4 and LPS+IL-4 compared to WT B cells, 
but only the difference in IgM secretion was significant. The decreased IgM and 
IgG production in vitro is consistent with the decreased B cell proliferation. Serum 
IgM was normal, IgG was low, and IgA was undetectable in the mutant mice. 
This profile is similar to that of ED-ID patients with the same mutation. Decreased 
isotype switching could be explained by the known role of NFκB in driving the 
expression of AID and germline transcripts in B cells32, as well as the structural 
defects preventing T and B cells from meeting their antigens.  Absence of PP in 
IκBα mutant mice is likely involved in their total lack of serum IgA. The normal 
serum IgM in IκBα mutant mice may reflect increased differentiation of their B 
cells into IgM producing plasma cells, because of the impaired isotype switching. 
Lack of specific antibody responses to vaccines has been documented in 
ED-ID patients with IκBα mutations9-11. Similarly, IκBα mutant mice did not 
produce specific antibodies to immunization with T-dependent or T-independent 
antigens. Defective TD antibody responses in IκBα mutant mice were expected 
from their failure to form GCs. However, TD antibody responses remained 
deficient in IκBα mutant chimeras, despite the formation of GCs. These findings 
suggest that failure to form GCs and an intrinsic B cell defect in responding to T 
cell help are both operative in the IκBα mutant mice. Given the importance of 
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CD40L-CD40 interactions in TD antibody responses, a likely element of this 
intrinsic defect in responding to TD antigen is the impaired response of IκBα 
mutant B cells to CD40 ligation. An intrinsic B cell defect was also demonstrated 
to underlie defective TI antibody responses in these mice, since these responses 
also remained deficient in the IκBα mutant Rag2-/- chimeras. Impaired responses 
to TLR and BCR ligation likely underlie the defective response of IκBα mutant B 
cells to TI type I and II antigens.  
The poor response to immunization is a two-fold problem, in that the 
mutant B cells do not respond well in vitro, nor can they form proper GC. In the 
IκBα mutant chimeras, even when FDCs were present and GCs were formed, 
they were not functional and did not produce specific antibody. A reduced B cell 
response to CD40 ligation may account for the lack of functional GCs in the IκBα 
mutant chimeras, as it would impair selection and T cell help. Given our results, it 
is likely that the reported failure of the patients to mount antibody responses to 
specific antigens is due to failure to generate antigen specific helper T cells 
because of potential lack of LN that drain the site of intramuscular antigen 
administration of TD antigens, as well as to an intrinsic B cell defect that impair 
their B cell responses to both TI and TD antigens. 
Based on our observations, the development of secondary lymphoid 
organs might be impaired in ED-ID patients with the IκBα S32I mutation, 
because of an intrinsic defect in non-hematopoietic cells. Furthermore, one would 
expect that allogeneic hematopoietic stem cell transplantation (HSCT) may fall 
short of reconstituting the immune response of these patients. There is no report 
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on the status of LN in these patients. However, it has been reported that the 
single patient with the S32I mutation who has survived HSCT does not have 
visible tonsils or palpable LN during infections. In addition, the patient has 
needed to be kept on intravenous gammaglobulin replacement therapy and 
prophylactic antibiotics. These findings are consistent with poor lymphoid 
organogenesis and persistent failure to mount protective antibody responses 
following HSCT. Current experiments are directly addressing this issue in our 
IκBα mutant mouse model. Failure of HSCT to correct lymphoid organogenesis 
and immune function in the mutant mice has important implications for the 
treatment of patients as it will strongly suggest that HSCT may not correct their 
immunodeficiency.   
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Why study primary immunodeficiency? 
The study of patients with primary immunodeficiency (PID) gives insights 
into the in vivo function of the different effectors of the immune system. This 
concept has been evident for the past 50 years since Dr. Robert A. Good 
described how PID bisected the microbial world into microbes that require T cells 
for clearance (i.e. opportunistic infections, fungi and systemically invasive 
viruses) and microbes that require humoral, antibody mediated immunity (e.g. 
encapsulated bacteria, and viruses that infect the mucosae)1. The consequences 
of mutations in genes that are important for immune cell development and 
function can vary from severe, sometimes fatal susceptibility to infection by a 
broad range of microorganisms, as in the case of genes that underlie severe 
combined immunodeficiency (SCID) with lack of T cells, to a narrow 
predisposition to infections by certain organisms, for example mycobacteria or 
Candida2, 3. Several genes have been discovered by studying patients with PID 
e.g. WASP4.  In addition, the function of several previously known genes has 
become better understood by the study of patients carrying mutations in those 
genes e.g. ATM, IL-7Rα3. 
Ectodermal dysplasia with immunodeficiency (ED-ID) is a PID with a 
clinical spectrum that includes susceptibility to recurrent pyogenic infections; 
hypogammaglobulinemia with low IgG and variable IgM and IgA; specific 
antibody deficiency, particularly to polysaccharide antigens; and decreased 
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cytokine and type I interferon production in response to TLR ligation5. Mutations 
in the NEMO gene were discovered to cause X-linked ED-ID when patients with 
ED-ID were compared to those with incontinentia pigmenti (IP). IP affects only 
women who are heterozygous for mutations in NEMO that abolish its activity. 
Patients with IP do not suffer from immunodeficiency because of non-random X-
inactivation. All male progeny of IP mothers who inherit the nonfunctional NEMO 
allele die in utero because NFκB activation depends on NEMO and is essential 
for normal cell survival. For the same reason, skin lesions are present in those 
few locations populated by the progeny of epidermal cells that have inactivated 
the normal X chromosome. Since it was known that amorphic mutations in 
NEMO caused IP, and that NEMO is essential for NFκB function, which is 
important for B and T cell responses, Zonana, et al hypothesized that “milder” 
mutations in NEMO may cause ED-ID6. However, as predicted by Zonana, et al, 
a number of groups reported the presence of hypomorphic NEMO mutations in 
males with ED-ID, while genes known to cause ED alone were found to be 
normal in the ED-ID patients6, 7. The function of NEMO has been studied by 
linking the mutation site to patient phenotype. Certain mutations are selectively 
associated with ED, deficient CD40 signaling, osteopetrosis, or specific 
infections8. 
Several PIDs with a defined clinical presentation have been found to be 
caused by mutations in genes that lie in the same signaling pathway. Examples 
include Hyper-IgM syndrome where mutations in the CD40 ligand, CD40, AICDA 
and UNG genes have been found9. Another example is T-B+ SCID where 
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mutations in IL-7Rα, IL-2γc and Jak3 have been reported10, 11. In the case of the 
canonical NFκB signaling pathway, mutations in NEMO and IκBα have been 
described, and we discuss in detail two novel mutations that have taught us 
important lessons about the function of these genes in ED-ID.   
The genes responsible for PID often carry mutations in their coding 
sequence. However this is not always the case. This is important to remember, 
as targeted exon sequencing and whole exome sequencing have reached clinical 
practice. In Chapter 1, we illustrated how a mutation in the 5’UTR of NEMO can 
cause disease by impairing mRNA and protein expression levels of NEMO. 
The majority of the genes known to cause PID to date are homozygous 
autosomal mutations, compound heterozygous autosomal mutations, or 
mutations on X chromosomes in males that impair protein function. However, in a 
number of cases a heretozygous autosomal mutation may also interfere with 
function by causing haploinsufficiency or by acting as a dominant negative. 
Examples of the former include TACI deficiency, where haploinsufficiency 
interferes with the response to T-independent type II antigens12, and C1 esterase 
inhibitor deficiency, which leads to uncontrolled activation of the complement 
system in response to infection and injury13. Autosomal dominant mutations 
include mutations in the STAT3 14 and Fas genes15. In Chapter 2, we described 
an IκBα mutation that results in functional insufficiency with 50% residual 
activation of NFκB. The resulting ED-ID phenotype is markedly milder than that 
of the S32I mutation in the same gene, which results in a dominant negative. The 
reasons for this difference are also discussed in Chapter 2. 
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The severity of the immunodeficiency that results from a mutation in a 
certain gene depends on at least three factors. One is the location of the 
mutation within the gene itself. This determines whether the mutant protein is 
present or absent, and if present, which of its biological activities is affected, how 
severely it is affected, and whether the mutant will act as a dominant negative. 
Another important determinant is the genetic background of the affected 
individual. The same mutation may result in variable degrees of disease severity 
in different siblings, since modifier genes in each child may be different. Finally, 
the clinical severity of the resulting PID depends on the microbial load in the 
environment. The latter point is best illustrated by the fact that Rag2-/- mice do 
well in a specific pathogen free (SPF) facility while RAG2 deficient infants 
uniformly die in their first year of life unless given hematopoietic stem cell 
transplant (HSCT). In Chapter 3, we have used a mouse knock-in model of ED-
ID on C57Bl6 background to circumvent the influence of variations in the genetic 
background and environment on the effect of the heterozygous S32I mutation in 
IκBα on immune cell development and function.  
 
Summary of studies of patients with ED-ID 
In Chapter 1, we reported a patient with recurrent infections, and a family 
history suggesting X-linked inheritance. Although this patient had no features of 
ED, he had deficient cytokine production in response to stimulation with TLR 
ligands in vitro. Furthermore, the patient’s cells exhibited decreased 
phosphorylation of IκBα, diminished IκBα degradation and impaired NFκB 
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activation following IL-1 stimulation. The patient’s cells were also found to have 
very low levels of NEMO mRNA and protein. Analysis of genomic DNA revealed 
no mutation in the coding sequence of the NEMO gene, but the presence of a 
novel mutation in the NEMO 5’ UTR. This mutation was the first to be reported in 
the 5’UTR of NEMO and was shown to result in aberrant splicing of the 
untranslated exons as evidenced by analysis of the cDNA. The fact that reduced 
NEMO expression and reduced NFκB activation resulted in impaired innate and 
adaptive immunity, but allowed normal ectodermal development strongly 
suggested a hierarchy in the requirement for NFκB activation for ectodermal 
development and innate immune responses. We suggested that NEMO protein 
levels should be examined in boys with dysgammaglobulinemia and an infection 
history consistent with a defect in NEMO, but whose NEMO sequence is normal. 
Decreased NEMO levels in such patients warrant examination of the 5’ and 3’ 
sequences to search for defects in transcription or mRNA stability, respectively. 
In Chapter 2, we presented the first case of a female with ED-ID caused 
by a heterozygous mutation in IκBα that resulted in N-terminal truncation of the 
protein. The mutation in this patient replaced the codon that encoded for a 
tryptophan at position 11 with a stop codon (W11X). The clinical presentation of 
this patient was milder than that of the two previously reported ED-ID patients, 
both of whom had a heterozygous S32I substitution that abrogated 
phosphorylation of the mutant. TLR function in our patient with the IκBα W11X 
mutation was impaired. The truncated IκBα protein did not undergo ligand-
induced phosphorylation or degradation following IL-1 stimulation. Moreover, 
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about 50% of the p65 NFκB subunit was retained in the cytoplasm by the mutant 
protein and NFκB DNA binding by nuclear extracts was decreased by ~50%. We 
have referred to this defect as a “functional haploinsufficiency”. 
 
How does the mis-spliced NEMO transcript affect protein levels? 
There are four first exons in the NEMO gene, 1A-D. They are each 
alternatively spliced to the ATG-containing second exon, resulting in mRNAs that 
are translated into an identical protein product. Lymphocytes express NEMO 
transcripts containing exons 1A, 1B and 1C but not 1D, spliced to exon 2. Exon 
1B-containing transcripts are much more abundant than transcripts containing 
exons 1A or 1C. Liver cells are reported to use exon 1D16. The patient’s exon 1B-
containing transcripts are mis-spliced, and we showed that his NEMO mRNA 
levels are decreased compared to normal controls, but we did not formally show 
that the mis-spliced exon 1B-containing transcripts are the cause for the low 
mRNA level. Biochemical studies would also allow us to measure the translation 
efficiency of the mis-spliced transcripts, as well as their stability in the cell. It 
would be interesting to show directly how the mutation affects the amount of 
mRNA and protein in different cell types. We postulate that the amount of NEMO 
in the patient’s liver is normal, because it relies less on exon 1B transcripts. 
However it is impossible to study this directly because liver material is not 
available from the patient. 
 
A mouse model of ED-ID with S32I mutation in IκBα  
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We have created a mouse model of ED-ID by introducing the S32I 
mutation into one allele of the IκBα gene. The mutant mice had ED, increased 
mortality, complete lack of lymph nodes and Peyer’s patches, and disorganized 
spleens that lacked follicles, marginal zone B cells and follicular dendritic cells. T 
cell function was normal in vitro, but contact hypersensitivity in vivo was severely 
impaired. B cell function in vitro and antibody response to T-dependent and T-
independent antigens were severely reduced. All immune defects, except those 
that affected B cell function, were absent in IκBα S32I mutant Rag2-/- bone 
marrow chimeras. This indicates that defects in stromal cells play a major role in 
the immunodeficiency of patients with ED-ID due to mutations in IκBα and other 
genes that impair the NFκB signaling pathway. This has important clinical 
implications, as bone marrow transplant may not be able to correct immune 
function in such patients. 
 
Why does the S32I mutation appear to be more severe than the N-terminal 
truncations of IκBα? 
It is expected that the product of a mutant non-degradable IκBα allele will 
be present at a higher level than the product of the WT allele, because both are 
equally subject to NFκB-induced expression but only the WT allele is degraded 
each time NFκB is activated. If this is the case, more than 50% of the NFκB 
molecules will be sequestered in the cytoplasm. In addition, if the mutant allele 
retains the capacity to engage the IKK complex, it will compete with the WT allele 
for the IKK complex.       
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Close examination of the Western blots of IκBα from the W11X17 and 
Q9X18 patients reveals three bands. The highest molecular weight band 
corresponds to normal-sized IκBα protein, the product of the WT allele. The 
middle band corresponds in size to the product of transcription reinitiation at Met 
13, and the lowest band to reinitiation at Met 37. The protein beginning at Met 13 
could possibly be phosphorylated and degraded, since it contains both the 
phosphorylation and ubiquitination sites. The protein beginning at Met 37 would 
contain neither, and has already been shown to act as a non-degradable inhibitor 
of NFκB19. The W11X patient has milder symptoms than the S32I patients 
because she may have a greater proportion of IκBα that can be degraded than 
the S32I patients, that is: the sum of the WT protein and the Met 13 protein. In 
addition, if the IKK complex anchors at the N-terminus of IκBα, her non-
degradable Met 37 mutant protein may not compete for IKK. This may explain 
why 50% of the IκBα is degraded in this patient, as demonstrated by retention of 
only 50% of p65 in the cytoplasm compared to 0% in the control following IL-1 
stimulation. This contrasts with phosphorylation of 10% of the IκBα in the S32I 
patient and of 30% in the IκBα S32I mutant mice.  
It should be noted that overexpression experiments showed that the IκBα 
W11X plasmid inhibited NFκB activation to the same degree as the IκBα WT 
plasmid in a reporter gene assay in transfected 293T cells. In contrast, Courtois 
et al, had reported that transfection of the IκBα S32I mutant, but not of WT IκBα, 
inhibited NFκB activation in 293T cells transfected with plasmids in comparable 
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amounts to what we used. The reason why they did not observe the expected 
inhibition of NFκB activation by the WT protein is unclear.  
 
Will bone marrow transplants in the S32I IκBα  deficiency restore immune 
function? 
 Transplant of mutant bone marrow into Rag2-/- mice showed that non-
lymphoid cells were necessary to form proper B cell follicles and germinal 
centers (GCs). The reverse experiment will also be necessary to see if mutants 
receiving WT bone marrow can respond to antigens. This important experiment 
will have direct clinical implications, since it would be similar to the hematopoietic 
stem cell transplants performed in patients and would indicate to what extent WT 
lymphocytes would be able to cure immunodeficiency in the patients. Since the 
non-lymphoid stroma of the mutant mice will still lack normal NFκB function, we 
hypothesize that the lymph nodes (LN) and Peyer’s patches (PP) may not be 
restored, and that the splenic architecture will continue to be disorganized. If this 
is the case, it will be unlikely to find mature follicular dendritic cells (FDCs) or GC 
formation in immunized IκBα mutant mice who have received WT bone marrow. 
In addition, specific antibody production will not be expected. The patient carrying 
the S32I mutation who survived transplant had an increase in his response to 
tetanus toxoid from a post-transplant immunization20. However the patient was 
reported not to have tonsils and not to have palpable LN during infection. It will 
be important to determine how T cells and B cells from the transplanted mutant 
mice respond to immunization both intraperitoneally and cutaneously. 
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Defective NFκB signaling in mutant mice 
In the case of the IκBα S32I mice, we cannot easily determine the ratio of 
protein expression from the mutant and WT alleles as we did in the W11X 
patient, since they are of the same molecular weight. Assuming efficient 
transcription from both alleles, it is quite interesting that only 20% of the protein is 
degraded after IL-1 stimulation. There are a couple of possibilities for why this is 
so. The mutant protein may build up in the cells. Upon stimulation, only the WT 
protein is degraded, but NFκB drives IκBα transcription from both WT and 
mutant alleles. A second possible reason is lower than expected degradation of 
the WT allele, because the mutant protein could compete for IKK binding and 
interfere with the phosphorylation of the WT protein.  
 
Are these mutations dominant negative?  
IκBα function can be represented by a spectrum of mutations. Normal 
mice would lie at the center of the spectrum, while IκBα-/- mice, with no IκBα 
function would lie at one end, and mice with the non-degradable IκBα would lie at 
the other. Since there is little NFκB negative regulation in IκBα-/- mice, there is 
increased inflammation and the mice die in the second week of life21. The IκBα 
S32I mice, which express non-degradable IκBα, have little NFκB signaling 
because of too much negative regulation. 
Since the IκBα mutations are gain-of-function mutations, are they 
necessarily dominant negative? The overall effect in the IκBα S32I mutant is loss 
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of more than 50% of NFκB signaling, thus they would fit the definition of 
dominant negative. We have no direct evidence that the mutant protein interferes 
with the function of product from the WT IκBα allele. In particular, IκBα is not 
known to dimerize. Thus the likely cause for the dominant negative effect is an 
excess of mutant protein, which in addition may also compete with the WT 
protein for IKK. It should be noted that IκBα+/- mice are completely normal and 
have no evidence of constitutive NFκB activation21. This suggests that there is 
normally an excess of IκBα over p50:p65 or that there is a compensatory 
increase in the level of IκBα to reset the normal IκBα:NFκB balance in IκBα+/- 
cells.  
 
How much NFκB activity is present in IκBα  mutant cells? 
 In order to compare NFκB function in the IκBα S32I model to WT mice, 
nuclear translocation of p50 and p65 in fibroblasts after stimulation with IL-1 or 
TNFα will be measured by Western blot. These experiments will help elucidate 
how much residual NFκB activity is present in the mutant cells. Other 
experiments in this vein include electrophoretic mobility shift assays (EMSA) in 
order to measure NFκB DNA binding in lysates after stimulation in fibroblasts, as 
shown in Chapter 2. Courtois, et al unexpectedly found that an excess of mutant 
IκBα S32I, but not of WT IκBα, inhibited NFκB luciferase activity. I plan to repeat 
this experiment in order to verify whether the mutant has a more inhibitory effect 
than the WT in a transient transfection assay, which would indicate a “true” 
dominant negative effect.  
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 As expected from impaired canonical NFκB signaling, IκBα mutant mice 
had no FDCs, B cell follicles or GCs in the spleen. Unexpectedly, they also had 
no LN or PP which have been reported to depend on the LTβR driven non-
canonical pathway of NFκB signaling22, 23. It is therefore important to examine 
directly whether the IκBα mutant protein interferes with the non-caninocal 
pathway. This could result from downregulation of p100 and RelB expression, 
which are subject to regulation by the canonical pathway. We will measure p100 
and RelB protein expression in MEFs and lymphocytes.   
It has been reported that LTβR also activates the canonical NFκB pathway 
to upregulate adhesion molecules, but relies on the non-canonical pathway to 
induce the expression of chemokines that are essential to attract LTi cells and 
lymphocytes22. We propose to study the upregulation of CXCL13, CCL19 and 
CCL21 in the MEF system by flow cytometry and quantitative PCR. A defect in 
this pathway would give further insight into the mechanism for the lack of LN 
formation and improper splenic architecture in these mice, as CXCL13 and its 
receptor CXCR5 are essential for successful secondary lymphoid 
organogenesis24. 
 
Are IκBα  mutant mice more susceptible to infection? 
 A quintessential question when considering whether a patient has an 
NFκB deficiency is the ability of the patient’s peripheral blood mononuclear cells 
(PBMCs) to produce cytokines after stimulation with a panel of TLR ligands25. 
Since IκBα phosphorylation and degradation after LPS stimulation was reduced 
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in fibroblasts and B cells (data not shown), it is expected that bone marrow-
derived macrophages and dendritic cells from IκBα mutant bone marrow would 
be impaired in their ability to secrete cytokines in response to TLR ligands. If this 
is the case, the mice would not be able to sense pathogens well and would be 
more susceptible to infection. 
 Susceptibility to infection has not been directly tested in these mice. The 
mice have been kept in autoclaved cages and on prophylactic antibiotics in an 
SPF environment. In order to more thoroughly characterize the phenotype, it 
would be necessary to keep some mice under conventional conditions in order to 
determine whether they develop any lesions, or are susceptible to opportunistic 
infections such as pneumocystis jiroveci, like ED-ID patients8, 26. We have shown 
that the response to TNP-LPS, TNP-ficoll and OVA immunization is defective in 
IκBα mutant mice. A next step would be to infect the mice with known amounts of 
a pathogen, such as Streptococcus pneumonia intranasally or Staphyloccus 
aureus cutaneously and evaluate bacterial clearance and inflammatory 
responses27. 
 
Are IκBα  mutant mice more susceptible to LPS shock? 
 As mentioned previously, IκBα phosphorylation and degradation following 
LPS stimulation was reduced. However, when the mice were immunized with 
TNP-LPS, some of the IκBα mutant mice died within a few days (6/7 mice in 
experiment 1, 3/6 mice in experiment 2). This is similar to the phenotype of the 
p50-/- mice that die from LPS shock. The phenotype is lymphocyte-independent 
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and depends on elevated levels of TNF28. It would be interesting to see if IκBα 
mice also produce high amounts of TNF after LPS administration, and if their 
survival in response to LPS is similar to p50-/- or p65+/-p50-/- mice. 
 
A closer look at immunoglobulin isotype switching in the IκBα  mutant mice 
Class switch recombination is also reported to require NFκB, as 
evidenced by germline transcripts and switching to certain Ig constant regions in 
p50-/- mice29. In the IκBα mutant mice, serum IgM was normal, serum IgG was 
low (due mostly to a defect in IgG1 subclass switching; data not shown) and 
serum IgA was absent. Mutant splenic B cells stimulated with anti-CD40+IL-4 or 
LPS+IL4 did not have a significant defect in IgG production. However these 
experiments used total B cells. We need to use naïve B cells to determine if 
isotype switching to IgG and IgE following anti-CD40+IL-4 and LPS+IL4 is 
impaired.  We will use LPS and TGFβ to examine switching to IgA. NFκB 
regulates the expression of IgG and IgE germ line transcripts and AICDA 
expression30. We will use quantitiative PCR to determine the expression of these 
genes in stimulated naïve B cells from mutant mice.    
 
Increased B1b cells in IκBα  mutant mice? 
One possible reason for why the IκBα mutant mice do not have low serum 
IgM may be that in the absence of normal isotype switching, the IgM+ B cells 
differentiate into plasma cells. Alternatively, the increased number of B1b-like 
cells which were found in the bone marrow (Fig. C.1) and spleen but not in the 
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peritoneum, may account for the normal serum IgM in the mutant mice. B1 cells 
produce natural antibodies and autoantibodies. We plan to explore the natural 
serum antibody levels to known antigens such as α-gal31 pneumococcal and 
other bacterial antigens. We will also screen the sera from IκBα mice for 
autoantibodies using a commercial screen for autoantigens.   
 
 
Figure C.1. B1b-like population in bone marrow from IκBα  mutant mice.  
The IgMhighB220low population is IgD-CD43+CD23lowCD11b+CD5-CD93-CD138-, consistent with 
B1b cells. A similar population was found in the spleens of IκBα mutant mice. 
 
Dermatitis in IκBα  mutant mice 
IκBα mutant mice develop skin lesions at varying ages with thickened 
epidermis and an intense dermal infiltrate of neutrophils, lymphocytes and 
eosinophils (Fig. C.2). Lesional skin becomes thick and scaly and the hair is lost. 
Even non-lesional skin contains more neutrophils than WT. Staining for bacteria 
was negative and we have failed to culture bacteria from these lesions. All mice 
have patches of hyperkeratosis, particularly around the eyes (data not shown); it 
is not known if this is immune in nature or if it is the mouse correlate of periorbital 
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Figure C.2. Dermatitis in IκBα mutant mice. 
A. H&E staining of sections from several tissues. B. Photos showing dermatitis and foot 
swelling in IκBα mutant mice. 
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wrinkling seen in some patients with ED. A small percentage of mice develop 
severe scaling and swelling of the feet. The dermatitis appears to be 
hematopoietically transferred, since one-quarter of the Rag2-/- mice that received 
IκBα mutant bone marrow also developed severe dermatitis. 
Dermatitis is not uncommon in NFκB family transgenic mice. IκBα-/- mice 
have perinatal lethality and severe inflammatory dermatitis21. Mice with a 
degradation-resistant IκBα (Δ1-36) transgene under the control of the 
Keratin5/14 promoter had TNFα-dependent keratinocyte hyperproliferation 
associated with immune infiltrates32. Skin grafts from RelA/c-Rel/TNFα triple KO 
embryos onto Rag-/- mice also develop TNFα-induced hyperplasia19. 
In order to better describe the dermatitis, we plan to stain the skin sections 
to look for Ig deposition and complement deposition, and to count various cell 
types in the infiltrate using H&E staining. T cell subsets in the infiltrate will be 
stained and enumerated by immunohistochemistry. Because of the presence of 
eosinophils in the infiltrate, IgE levels will also be compared between affected 
and unaffected IκBα mutant mice and their WT littermates. Expression of 
cytokines and chemokines in the lesional and non-lesional skin of mutant mice 
will be analyzed by quantitiative PCR and compared to that in skin of WT 
littermates. 
 
T cell development 
 Skin-resident regulatory T cells (Treg) are essential for maintaining normal 
immune homeostasis in the skin33, and the Treg deficient scurfy mice develop skin 
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inflammation that can be transferred to Rag1-/- recipients34. We have evidence of 
a 3-fold decrease in the number of CD25+Foxp3+ regulatory CD4+ T cells in the 
spleen (data not shown). We plan to analyze Treg cell function. The mice will be 
bred with Foxp3-EGFP mice and EGFP+ cells will be sorted and their function 
assessed using standard assays35.  
 While the numbers and percentages of T cell subsets in the thymus from 
IκBα mutant mice appeared to be intact, there was abnormal thymic architecture. 
Further immunohistochemical studies on the thymus will show whether there is a 
defect in thymic epithelial cell development, and whether there is proper AIRE 
expression. If AIRE expression is impaired, there is a possibility that T cells 
escape from negative selection and contribute to autoimmunity and dermatitis in 
these mice. To address this issue we will analyze the T cell repertoire of these 
mice by flow cytometry and analysis of Vβ region expression. 
 
Conclusion 
 Through these mouse model experiments we will gain insight into the 
consequences of impaired NFκB signaling due to the IκBα S32I mutation, a 
mutation that severely impairs NFκB signaling and results in severe disease that 
appears to be not well controlled by bone marrow transplantation. 
ED-ID covers a spectrum of patient presentations depending on the 
location of the mutation within the gene and the gene affected. NFκB signaling is 
complex with interplay between the canonical and non-canonical pathways. The 
lessons we will learn from these studies may be applicable to other mutations 
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that severely impair NFκB signaling and have important implications for the 
treatment of patients who carry these mutations. 
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